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ABSTRACT 
 
Bone is a dynamic tissue, where bone forming osteoblasts and bone resorbing osteoclasts 
maintain homeostasis. Research into bone toxicology has largely focused on 
pharmaceutical side effects adversely affecting bone development. However, many 
environmental toxicants can regulate bone homeostasis. Recently, the nuclear receptor 
peroxisome proliferator activated receptor gamma (PPARγ) has emerged as an important 
target of environmental toxicants. PPARγ dimerizes with the retinoid-X receptor alpha 
(RXRα), is a central transcription factor in adipogenesis, and in bone can 
transdifferentiate osteoblasts into adipocytes by suppressing osteogenic pathways. The 
central hypothesis of this dissertation is that environmental chemicals can adversely 
affect bone homeostasis by activating nuclear receptors in bone cells – particularly 
osteoblasts and osteoclasts – to perturb cellular differentiation and function. Three study 
aims were developed to test and refine this hypothesis. First, a set of structurally diverse 
environmental PPARγ agonists were individually applied to mouse primary bone marrow 
mesenchymal stromal cell cultures undergoing osteogenic differentiation. In vitro PPARγ 
ligand treatment suppressed osteogenesis and stimulated adipogenesis. Organotin 
 vii 
compounds (tributyltin, triphenyltin) in particular more efficaciously suppressed 
osteogenesis. The second aim characterized the effects of in vivo tributyltin exposure on 
bone microarchitecture in female C57Bl/6 mice. Tributyltin exposure resulted in a thinner 
cortical bone, but significantly increased trabecular mineralization. Further analyses 
suggested that tributyltin did not suppress osteoclast numbers but rather changed 
osteoclast function, minimally attenuating the resorptive function and enhancing their 
ability to generate osteogenesis-stimulating factors. Furthermore, tributyltin activated not 
only PPARγ, but also RXR and liver X receptors. The third aim established the utility of 
Generalized Concentration Addition in modeling PPARγ activation by mixtures of full 
and partial PPARγ agonists. A complex mixture of multiple phthalate compounds 
activated an in vitro PPARγ reporter assay, and the individual dose-responses of each 
compound were used to construct modeled responses. The comparisons of empirical data 
and model predictions supported the use of Generalized Concentration Addition in 
modeling a complex mixture of environmental PPARγ agonists. Together, these studies 
support and establish important toxicological mechanisms related to PPARγ and RXRα 
activation in different aspects of bone biology and provide a basis for studying mixture 
effects of PPARγ agonists.  
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CHAPTER I:  Introduction 
 
The importance of the proper function and maintenance of the skeleton cannot be 
understated, given its multiple roles in protecting the organs, providing a structure that 
allows mobility, providing a niche for hematopoietic development, and acting as an 
important mineral depot. However, bone as a target of environmental toxicants has 
gained disproportionately little attention compared to other organ systems, and studies 
characterizing toxic mechanisms in bone have largely been in the context of 
pharmacological interventions. Despite the fact that numerous classes of environmental 
chemicals can affect bone homeostasis through a variety of mechanisms, bone as a target 
of environmental toxicants is especially understudied.  
A number of these environmental toxicants have receptor-mediated mechanisms 
of action. One such receptor is the peroxisome-proliferator activated receptor gamma 
(PPARγ), a nuclear receptor belonging to the class of retinoid-X receptor alpha (RXRα) 
heterodimers. This receptor is central in lipid homeostasis and is influential in the 
differentiation of bone cells. The identification of novel environmental PPARγ toxicants 
and the known role of PPARγ in bone provide the possibility that exposure to these 
environmental ligands contributes to the incidence of bone pathologies. 
The section below provides a background for studying environmental nuclear 
receptor ligands, including PPARγ ligands, in the context of receptor-mediated 
toxicology and bone physiology. 
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The nuclear receptor superfamily 
The nuclear receptor superfamily provides the mechanisms by which lipophilic 
hormones and hormone-like chemicals modulate gene transcription. This family of 
protein receptors has a specific macromolecular structure that permits coordinate binding 
of a ligand (e.g. a hormone, toxicant, or any molecule that binds a receptor) to the 
receptor and the receptor to DNA to initiate transcription of target genes. These receptors 
are located either in the cytoplasm or the nucleus and may be bound by co-repressor 
proteins that suppress their transcriptional function until they are released.(1–3)  
Most nuclear receptors exert their mechanism of action as either a homodimer (a 
pairing of the same receptor) or a heterodimer (a pairing of two distinct receptors). 
Examples of nuclear receptor homodimers are found among the steroid receptor 
subfamily of nuclear receptors, which includes the estrogen receptor (ER) and androgen 
receptor (AR), both of which bind to DNA as identical pairs (i.e ER:ER or AR:AR, 
respectively) to modify reproductive physiology (among other important endpoints).(1–3)  
A second class of nuclear receptor dimers is the retinoid-x receptor (RXR) 
heterodimer subfamily.(4–6) The retinoid-X receptor alpha (RXRα, which belongs to a 
subclass that also includes the retinoid-X receptors beta and delta) heterodimerizes with 
several other structurally distinct receptors, including, but not limited to, the vitamin D 
receptor (VDR),(7) the retinoic acid receptor (RAR),(5,7) thyroid hormone receptor (TR),(7) 
the liver-x receptors alpha and beta (LXRα and LXRβ)(8) and the peroxisome proliferator 
activated receptors (PPARs).(9–12) Pathways involving RXRα heterodimers have been 
shown to be important in many tissues, including bone, where RXRα:RXRα 
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homodimerization(13) and RXRα:LXRα or RXRα:LXRβ(13,14) heterodimers suppress bone 
loss and have been identified as potential therapeutic targets. On the contrary, the 
RXRα:PPARγ heterodimer acts to suppress bone formation.(15,16) The contribution of 
these receptor pairings in bone homeostasis will be discussed in greater detail in the 
sections and chapters below. 
 
Nuclear receptor activity 
The activity of a nuclear receptor can be quantified by the expression of a target 
gene, and is sensitive to the concentration of ligand present and available to bind the 
receptor. When a ligand acts to increase activity of a nuclear receptor, the ligand is 
generally termed an agonist; conversely, an antagonist is a ligand that acts to suppress or 
inhibit the function of a receptor (Chapter IV will provide a more specific definition of 
the latter, namely competitive antagonism). In either case, the trend describing the 
activity of the receptor as a function of ligand concentration is known as the ligand’s 
dose-response. For nuclear receptors, this function tends to be non-linear over a range of 
ligand concentrations and is commonly referred to as the dose-response curve. The most 
basic theory behind this mechanism is occupation theory, which makes a number of 
assumptions, including, but not limited to: the binding of the drug (toxicant) to the 
receptor is reversible; the observed response is proportional to the concentration of 
agonist-receptor complexes; and a maximal stimulus occurs when all of the receptors are 
occupied.(17) 
Three important parameters describe the shape of a dose-response curve for 
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nuclear receptor activation (which is typically presented on a semi-log plot, with log 
agonist concentration on the x-axis, and response on the y-axis): the maximal effect level 
at which the curve plateaus (the efficacy); the concentration at which the curve reaches 
half maximal efficacy (in the case of an agonist, the effective concentration of the agonist 
producing 50% maximum efficacy (EC50)), which is commonly referred to as potency; 
and the steepness of the curve.  
The relation of these three parameters can be described by the function: 
 
𝐸 =  
𝑎[𝐿]
𝐸𝐶50 + [𝐿]
 
 
Where E is the observed effect level; 𝛼 is the curve maximum (efficacy) and [L] 
is the ligand concentration. The concentration of the receptor is assumed to be constant. 
A detailed derivation and discussion of this equation, along with relevant assumptions 
under occupation theory, can be found in Kenakin, Pharmacologic Analysis of Drug-
Receptor Activation, 3rd. Ed. (Lippincott-Raven, 1997).(17)  
More complex models, which factor in induction of enzymes, increases in 
receptor concentration, or cooperativity of multiple-ligand binding, have also been 
developed.(17) However, the above equation is, in some cases, suitable for describing the 
most proximal (i.e. initial) events of toxicants binding and activating a nuclear receptor 
and potentially its observed downstream effects as well.  
  
5 
 
 
Structure and specificity in nuclear receptor activity 
Nuclear receptors have a canonical structure comprised of subunits that show 
various levels of conservation among all nuclear receptors. The two most notable 
structural subunits of nuclear receptors are the ligand-binding domain (LBD) and DNA-
binding domain (DBD), both of which vary in structure among nuclear receptors to 
confer specificity of function.(2,18,19)   
The DBD allows for specificity in gene expression via selective DNA binding. 
The sequences of amino acids that comprise the DBD confer a particular structure that 
permits stable interaction between the receptor and DNA at specific nucleotide sequences 
termed response elements. For example, PPARγ:RXRα heterodimers bind to a pairing of 
hexameric sequences of nucleotides that are separated by a single nucleotide spacer, in a 
conformation designated as a DR-1 sequence (for “direct repeat” with a 1-nucleotide 
spacer).(2,20,21) Genes that contain a DR-1 sequence in their promoter region are therefore 
targeted for transcription by activation of PPARγ:RXRα.(22,23)   
The LBD confers specificity of activation by the structure determined by the 
sequence of amino acids in the ligand binding pocket. This allows the nuclear receptor to 
discriminate among the ligands that it can bind. The shape of the ligand also indirectly 
determines the set of co-activators recruited to the receptor:DNA complex. These co-
activators replace the co-suppressors (which inhibit transcription) and subsequently 
aggregate the transcriptional machinery (including RNA polymerase). This mechanism 
allows for differential efficacies among ligands.(2,18,19,24,25)   
 
6 
 
 
The PPARγ/RXRα heterodimer 
PPARγ has gained considerable attention in the past three decades when 
Spiegelman and others discovered it to be a ligand-activated transcription factor central in 
the generation of adipocytes, a process termed adipogenesis. The precise identification of 
PPARγ:RXRα as the transcription factor controlling the adipocyte-specific fat enhancer 
ap2 (fatty acid binding protein 4, FABP4)(26–29) came in parallel with the discovery that 
PPARγ was also the target of insulin-sensitizing drugs belonging to the thiazolidinedione 
class of therapeutics, which includes the compounds pioglitazone and rosiglitazone.(30) 
The latter has become the experimental agonist of choice for parsing the mechanism of 
action of PPARγ as it serves multiple roles as an insulin sensitizer, adipogenic 
transcription factor, and determinant of mesenchymal stromal stem cell fate in bone.(31)   
PPARγ is expressed as two transcript variants: PPARγ1 and PPARγ2.(32) 
Although both are influential in adipocyte differentiation (and highly expressed in white 
and brown adipose tissue),(27,33) PPARγ2 is more selectively expressed in adipocytes(27,29) 
and its variable activity is more sensitive to the action of exogenous ligands.(34,35) The 
two isoforms differ by 30 amino acids added to the proximal end of the N-terminus of 
PPARγ2, which contains the DNA binding domain.(27) The N-terminal domain also 
serves as a regulatory target. The proximal 120 amino acids contain multiple serine 
residues that can be phosphorylated by MAP kinases to inhibit the transcriptional activity 
of the receptor.(36) Recent work has shown that certain PPARγ ligands can also block 
phosphorylation of these residues, and specific phosphorylation events can selectively 
modify the gene targets of PPARγ.(37) This imparts selectivity in PPARγ activation, and 
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current research seeks to identify therapeutics that selectively activate PPARγ’s insulin 
sensitizing effects while suppressing its adipogenic effects via kinase pathways.     
Dissection of the events leading to adipocyte differentiation has established 
PPARγ as an essential driver of the transition from pre-adipocytes to mature, terminally 
differentiated adipocytes.(38,39) Early adipocytes express transcription factors belonging to 
the basic helix-loop-helix CAAT/enhancer binding protein (C/EBP) family.(40) Two 
members of this family, C/EBPβ and C/EBPδ, induce transcription of PPARγ by binding 
to the PPARγ promoter.(41) PPARγ, under ligand activation, induces transcription of a 
third C/EBP: C/EBPα.(42) This protein subsequently binds to the PPARγ promoter, setting 
up a positive feedback loop that sustains the level of PPARγ expression.(43) C/EBPα 
cannot induce adipocyte differentiation in the absence of PPARγ.(44) In contrast, the 
expression of C/EBPα is not necessary for adipocyte differentiation (as it is not necessary 
for the initial transcription of PPARγ).(44) This implies that the functional consequences 
of PPARγ activity are supported by a feedback loop that maintains a basal level of 
PPARγ in cells.(43)  
However, the primary driver of PPARγ activity, and thus its downstream effects, 
is ligand binding. Endogenously, prostaglandin compounds (e.g. 15-deoxy-Δ-12,14-
Postaglandin J2), which are long-chain fatty acids that serve primarily a paracrine 
function in fat tissue, bind and activate PPARγ.(45) For exogenous ligands, much of the 
research on PPARγ activity has focused on thiazolidinedione therapeutic compounds 
(used in treatment of type II diabetes), such as rosiglitazone, noted above.  
The C-terminal domain of PPARγ is recognized as the major region that binds 
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chemical ligands (e.g. rosiglitazone) as well as cellular proteins (e.g. RXRα and 
coactivator proteins like PGC-1a).(25,31,46,47)The LBD contains a large binding pocket with 
many hydrophobic residues capable of binding a variety of lipophilic ligands.(48,49) 
Because co-activators also bind to this domain, the specific, dynamic interaction of the 
ligand with the binding domain causes conformational shifts that expose variable residues 
that interact with different co-activators.(25,50) In turn, these co-activators contribute to the 
transcriptional efficiency of receptor/enzyme complex. Research into co-activator to 
PPARγ/RXRα heterodimer interaction has identified variability in coactivator 
recruitment with different ligands.(51,52) In combination with variable affinities for the 
ligand binding domain among PPARγ agonists, PPARγ ligands therefore can vary in 
efficacy and potency. 
Prior to these events, it is believed that PPARγ:RXRα dimerization occurs in 
solution, where interactions between the LBDs and the DBDs stabilize the dimer and 
allow for high-affinity binding to DR-1 sequences along the DNA.(4,31,53) It is also notable 
that Chandra et al. (2008) found that ligands for PPARγ with distinct properties (an 
agonist, rosiglitazone and an inhibitor, GW9662) elicited the same conformations with 
respect to domain interactions within the heterodimer.(46) This suggests that differences in 
the effects of PPARγ ligands is not likely to be due to changes in PPARγ:RXRα dimer.  
For RXR heterodimers, the orientation of the receptor complex is important.(18,50) 
For example, RXRα is positioned upstream of the thyroid hormone receptor when the 
RXRα:TR heterodimer is bound to DNA.(54) Binding of a ligand to RXRα alone does not 
initiate transcription (it requires a ligand for TR), and as such the dimer is referred to as 
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“non-permissive”. Conversely, RXRα is positioned downstream of PPARγ in the 
PPARγ:RXRα heterodimer.(20,46,50) As a consequence, ligand binding to either receptor 
can initiate transcription; this pairing is termed a “permissive” heterodimer. This 
distinction is important when considering the suite of receptors with which RXRα can 
dimerize, and whether the function of an RXR partner can be induced by activation with 
an RXR-specific ligand, as is the case with PPARγ:RXRα. 
To summarize the above, PPARγ is an essential factor in the formation of 
adipocytes, as evidenced by its controlling role in adipocyte differentiation, its expression 
levels in mature fat cells, and a host of experiments demonstrating PPARγ ligand efficacy 
in adipocyte accumulation. It forms an obligate, permissive heterodimer with RXRα, 
which allows for binding to specific regions of DNA that control adipogenic genes. 
Transcriptional activation of the PPARγ:RXRα heterodimer is accomplished by ligands 
for either receptor, where variation in response is believed to be controlled, at least in 
part, by ligand-selective co-activator recruitment.  
 
PPARγ as a target of environmental obesogens 
The notion that exposure to environmental toxicants contribute to obesity on a 
population-wide level was proposed in 2002 in a “provocative”(55) paper by Baille-
Hamilton.(56) Citing the concurrent increase in chemical use and obesity rates in the 
United States, this hypothesis posited that commonly attributed lifestyle factors, such as 
physical activity, diet, as well as genetic factors, could not fully account for the observed 
increases in adipose body mass, and asserted that chemical exposure was a driving factor 
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in obesity.(56)  Drawing upon mechanistic research detailing the effects of chemicals that 
interact with the endocrine system to disrupt metabolism, Grun and Blumberg coined the 
term “obesogen” to classify chemicals that acted to “inappropriately regulate lipid 
metabolism and adipogenesis to promote obesity”.(57) Obesogens have since emerged as a 
special class of endocrine disrupting chemicals that potentially contribute to obesity and 
dysregulation of lipid metabolism. 
Due to its role as a master regulator of adipogenesis, PPARγ was quickly 
established as a putative target of obesogenic chemicals. Among the first chemicals to be 
classified as such was tributyltin (TBT), which several groups showed could activate 
PPARγ and induce adipogenesis in vertebrates.(58,59) In vivo, tributyltin enhances fat 
formation,(59,60) even transgenerationally.(61) Importantly, organotin compounds also bind 
and activate the RXRα receptor, establishing them as dual PPARγ:RXRα agonists.(62,63) 
However, the obesogenic (i.e. adipogenic) effects of TBT require PPARγ.(60) 
Over the past several years, numerous other environmental contaminants have 
been identified as PPARγ agonists. These include phthalate metabolites (e.g. mono-ethyl 
hexyl phthalate (MEHP), mono-ethyl tetra-bromo phthalate (METBP);(64–66) brominated 
flame retardants (tetrabromo bisphenol-a);(67) and fungicides (triflumizole, 
triphenyltin).(58,68) PPARγ is a recognized toxicological target in the EPA’s ToxCast and 
Tox21 high-throughput screening initiatives, and a major component of the adipogenic 
ToxPi category.(69,70) The assays in ToxCast and Tox21 are designed to identify 
compounds that activate or interact with PPARγ along mechanistic pathways related to 
adipogenesis, and in the case of ToxPi, prioritize compounds by potential for endocrine 
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disrupting toxicity. As the biology of PPARγ activation and chemical adipogenesis 
becomes further characterized, these screening assays will be increasingly useful in 
identifying important links between environmental chemical exposures and adverse 
effects related to fat metabolism (though the utility of PPARγ activation screens has 
recently come under criticism).(71)  
 
Obesogens and bone 
PPARγ is expressed in bone marrow mesenchymal stromal cells (BM-MSCs), as 
well as bone resorbing osteoclasts.(72) Research into the consequences of PPARγ 
activation BM-MSCs identified an adverse pathway of transdifferentiation, whereby 
osteoblastogenesis was replaced by adipogenesis in a PPARγ-dependent manner.(15,73) In 
brief, activation of PPARγ by an exogenous ligands, such as rosiglitazone, suppresses the 
activity of key osteogenic transcription factors (transrepression), and upregulates 
adipogenic genes. Consequently, the increased marrow adiposity and decreased 
mineralization accelerate an “aging-like phenotype” of lower bone quality.(74–76) This 
phenotype has been observed in numerous clinical studies of older individuals taking 
glitazone drugs, and represents a significant off-target effect for diabetes therapeutics that 
target PPARγ.(77–79) 
With the identification of environmental PPARγ ligands such as tributyltin, bone 
has been identified as a target of environmental obesogens.(60,61,80–82) This mechanism is 
investigated in depth in Chapters II and III. To provide a basis for the disruption of bone 
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homeostasis by these compounds, an overview of bone biology and endogenous factors 
that control bone development is presented below. 
   
Relevant aspects of bone biology 
Bone structure and turnover 
Bone tissue can be divided into two types of macroscopic structure: cortical and 
cancellous bone. Cortical bone is dense and found in greater proportion in long bones 
(such as the femur and tibia), and makes up roughly 80% of the mass of the skeleton. 
Cancellous bone is less dense and comprises only about 20% of skeletal mass, but forms 
a network of branched and interconnected structures (trabeculae) that provide about 80% 
of the skeletal surface area.(83) With the hard, cortical shell surrounding the network of 
trabecular bone, the skeleton is able to meet and adapt to various demands – both 
physical and biochemical – imposed on the body.  
Bone is a dynamic tissue. Despite being composed predominately of hard, 
hydroxyapatite mineral (consisting of calcium and phosphate) surrounding collagenous 
protein, bone undergoes processes that alter its physical makeup: the distinct, cell-
mediated activities of bone growth (modeling) and coupled bone growth and resorption 
(remodeling). Bone modeling is crucial in development and achieving peak bone mass, as 
well as responding to physical stress to strengthen the mechanical properties of the 
skeleton.(84,85) 
The purpose of bone remodeling is two-fold. First, the skeleton must respond to 
mechanical stress, from the microscopic to the catastrophic. The process of repairing 
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fractures requires bone first to be resorbed.(85) Second, the bone matrix serves as a storage 
depot for calcium and phosphate. Release of these resources to serve various other 
purposes in the body requires a dissolution of the mineralized tissue. Hence, bone 
remodeling is in part under control of the endocrine system (e.g. parathyroid hormone 
and steroid hormones, discussed below) and contributes to whole-body homeostasis.(86)     
Bone homeostasis is a careful balance of the two processes of bone remodeling, 
and pathologic states can result from an imbalance in formation and resorption. For 
example, an imbalance that favors bone formation (e.g. by impairments to bone 
resorption) may result in osteopetrosis (a.k.a. “marble bone disease”), which is associated 
with a disproportionate number of fractures and arthritis, among other symptoms.(87,88)   
Conversely, and perhaps more widely recognized, are conditions such as 
osteopenia and osteoporosis, which are characterized by excessively low bone density 
that can lead to fracture. This absence of bone can be caused by an impairment of bone 
formation, an increase in bone resorption, or both. Accordingly, therapeutics for 
osteoporosis, such as bisphosphonates and parathyroid hormone, attempt to alleviate the 
loss of bone by targeting the remodeling process to shift in favor of formation.(89,90) 
With advanced age (discussed below), bone remodeling inevitably shifts in favor 
of resorption so that each cycle of remodeling results in a net loss of bone. Because the 
balance of formation and resorption must be very tightly regulated in order to maintain 
bone homeostasis throughout growth and development, and in the midst of mineral and 
structural demands, control of the process is carried out locally by communication among 
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specialized, interacting cells. The three types of cells that determine bone remodeling are 
osteoblasts, osteocytes, and osteoclasts. 
 
Cellular functions in bone remodeling 
Osteoblasts are responsible for generating the mineral matrix.(91,92) These cells are 
derived from the mesenchymal lineage (BM-MSCs) and differentiate in response to local 
signals that include soluble proteins from the Wnt family(93) as well as the bone 
morphogenic protein (BMP) family.(94) The key transcription factor activated by these 
signals (and other factors) is Runx2,(95) the activity of which is maintained at low levels 
due to negative regulation by PPARγ.(96) Wnt signaling, for instance, can remove this 
negative regulation(97,98) by upregulating the activity of beta-catenin, which allows for 
Runx2-dependent transcription of osteogenic genes such as Sp7 (osterix)(99) (conversely, 
PPARγ activation can transrepress Wnt signaling by preventing the nuclear localization 
of beta-catenin).(100)   
As the osteoblast matures, it begins to express proteins that provide conditions for 
the nucleation of crystalline calcium and phosphate, as well as high expression levels of 
collagen. Together, these structural elements make up the solid yet flexible bone tissue. 
As the matrix develops, the mature osteoblast may line the bone surface in a quiescent 
state, undergo apoptosis, or be embedded in the mineral where it fully matures into an 
osteocyte.(101–103)  
Osteocytes – which are by far the most prevalent cell type, making up ~90% of 
bone cells – are readily identified by their distinctive shape, which features a number of 
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dendritic process that extend into the surrounding mineral.(104) This morphology allows 
for osteocytes to serve as force transducers, sensing minute changes in the mechanical 
stress on bones and responding to initiate remodeling. These cells orchestrate the 
remodeling process via secretion of soluble factors that can promote mineralization (e.g. 
Dmp1, MEPE, FGF23), or, in a negative feedback manner, inhibit formation and 
stimulate resorption.(101–103,105,106) 
The third type of cell – osteoclasts – are bone resorbing (dissolving) cells that 
differentiate from bone marrow myeloid progenitors (of the hematopoietic lineage) and 
fuse to form large, multinucleated cells. Expression of the transcription factor Nfatc1 is 
necessary and sufficient to induce osteoclastogenesis, which leads to the expression of 
downstream target genes specific to osteoclasts, such as Acp5/Trap (a phosphatase),(107) 
Dc-stamp (involved in cell fusion),(108) and Ctsk (bone resorption),(109) along with 
autoamplification of Nfatc1 to provide a positive feedback mechanism.(110–113)  
Osteoclasts feature an outer membrane that tightly attaches to the bone surface to 
create a sealed area. The membrane inside this sealed zone forms a ruffled border, 
creating a greater surface area from which the cell can secrete the resorptive enzyme 
cathepsin K,(109,114) along with protons to acidify the sealed resorption region. Dissolution 
of the mineral surface produces visible resorption pits, the identification of which can be 
used to assess osteoclast function both in vitro and in vivo. Digested materials, along with 
the osteoclast specific protein tartrate resistant acid phosphatase 5b (TRAP5b), are 
endocytosed, passed through the cell and ultimately secreted into the blood stream, where 
they can be detected as biomarkers of bone turnover.(107,115) High concentrations of 
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calcium in the resorption area generated by the demineralization of the matrix leads to 
osteoclast apoptosis and the cessation of bone resorption.(116) 
The current paradigm of bone turnover asserts that mature osteoblasts are then 
recruited to the newly formed resorption pits where mineralization can proceed. This 
stimulation may come from soluble factors released from the mineral matrix during 
resorption,(117) though direct communications between osteoclasts and osteoblasts also 
stimulate the reversal phase of bone turnover.(118) These mechanisms and other 
communication signals among the three cell types are discussed below. 
 
Cell-cell communication in bone remodeling  
Tight regulation of the remodeling process is carried out locally by 
intercommunication by the three cell types. Perhaps the best characterized aspect of 
turnover communication is the stimulation of osteoclast differentiation by osteoblast-
derived receptor activator of NFκB ligand (RANKL).(119,120) Expression of RANKL 
protein in osteoblasts can be promoted by vitamin D and parathyroid hormone, among 
other factors.(121) Current research suggests that membrane-bound RANKL is most 
effective in inducing osteoclastogenesis (rather than soluble, secreted RANKL), 
consistent with the notion that cell-cell contact is the main driver.(122) In osteoclasts, 
expression of the receptor RANK is upregulated by the essential soluble macrophage 
colony stimulating factor (M-CSF) (also produced by osteoblasts);(123) stimulation of 
RANK by RANKL is the major upstream event that drives expression of Nfatc1.(124)  
Osteoblasts also secrete an inhibitory factor to counter this communication signal: 
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osteoprotegerin (OPG).(120,125) OPG is a “decoy” receptor for RANKL, and thus interferes 
directly with RANKL signaling. The ratio of RANKL expression to OPG expression 
commonly is used as a measure of osteoclastogenic potential in osteoblasts, where lower 
ratios are associated with larger measures of bone formation.  
The matrix-entombed osteocytes can serve as negative regulators of 
osteoblastogenesis via soluble factors. One such factor is sclerostin (Sost), which inhibits 
the Wnt pathway by preventing a necessary dimerization between the Frizzled and LRP 
receptors to which Wnt proteins bind.(106,126) Genetic deletion of Sost in mice leads to 
high bone mass, and loss of sclerostin in humans may lead to multiple types of high-
density bone disorders.(127,128) The regulation of sclerostin expression provides a 
mechanism by which exogenous and endogenous signals can couple with bone 
metabolism: Sost expression is negatively correlated with mechanical strain in osteocytes, 
linking anabolic effects of bone with stress recovery.(129) Parathyroid hormone also 
downregulates Sost in osteocytes, allowing for a recovery of bone mass following 
increased osteoclast activity.(130)  
Osteocytes are also known to express RANKL and OPG, as well as M-CSF, to 
directly control osteoclast differentiation. This occurs during osteocyte apoptosis in order 
to recruit osteoclasts to the resorption surface, as well as during states of mechanical 
unloading.(131,132) Thus, osteocytes serve as regulators of both bone formation and 
resorption via secreted signaling mechanisms.  
The communication from osteoclasts to osteoblasts is less clearly understood. 
Following resorption is a “reversal” phase of bone remodeling, in which mature 
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osteoblasts replace the lost bone.(133) This requires a stimulatory signal to osteoblasts. 
Conditions of osteopetrosis resulting from non-resorbing (but present) osteoclasts (i.e. 
osteoclast-rich osteopetrosis) indicated that some form of pro-osteogenic signaling was 
being produced by osteoclasts even in the absence of resorption.(134) 
  Among these signals are excreted Il-6 family cytokines which include the protein 
cardiotrophin-1 (CT-1).(135,136) CT-1 acts via membrane-bound receptors on osteoblasts to 
stimulate Runx2.(135) On the other hand, mature osteoclasts also express inhibitory 
proteins, such as Sema4d, that act via cell-cell contact to prevent osteoblast activity.(137) 
The inhibitory signaling from direct contact and stimulatory signaling from soluble 
factors may serve to establish a temporal and spatial separation between resorption and 
formation, as well as potentially protect osteoblasts from the highly acidified 
microenvironment.  
All three cell types display supportive and inhibitory communication signals 
toward one another, the above mechanisms being only a few of the major examples. The 
presence of redundant and feedback-responsive mechanisms highlights the importance of 
careful regulation of bone remodeling to maintain homeostasis. However, even under 
normal conditions of bone homeostasis, multiple physiological factors can modify this 
balance.  
 
Age and sex as co-determinants of bone homeostasis 
The age and sex of an animal are highly influential in determining the rate of bone 
turnover and thus macroscopic bone structure. During early development (before peak 
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bone mass is achieved), bone deposition occurs along the outside (periosteal) surface of 
long bones, while resorption occurs along the inside (endosteal) surface.(138,139) Although 
the thickness of the cortical shell decreases over the course of this process, the net result 
is a widening of bone, providing greater structural stability and resistance to 
bending.(140,141) These changes in bone geometry are generally more pronounced in 
males, specifically periosteal apposition,(138,139,142–144) and are largely established during 
puberty.(144) Endocortical resorption is similar between males and females during growth, 
as is bone mineral density normalized to bone volume (volumetric bone mineral 
density).(139,145) Thus, males tend to have stronger bones and lower rates of fracture 
because of greater bone apposition producing larger bones. Decreases in the apposition of 
bone on the periosteal surface during the growth phase therefore may attenuate peak bone 
mass, exacerbate the consequences of bone loss, and increase the risk of fractures later in 
life.(143,146)  
Once peak bone mass has been achieved in young adulthood, apposition slows but 
resorption continues and remodeling becomes an overall negative process. During 
development, males had greater bone growth in the trabecular compartment. Thus, the 
loss of trabecular bone continues for a longer period compared to females; the increased 
surface area provides for more available bone to be resorbed. In males, trabeculae 
generally thin with age, whereas in females, the trabeculae become perforated and 
completely resorbed.(139,147) As the trabeculae disappear, bone resorption occurs to a 
larger extent along the endosteal surface.(139)  
In the bone marrow, the number of mature adipocytes increases with age, 
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resulting in “fatty marrow”.(148–150) This is due to a greater potential of BM-MSCs in aged 
animals to differentiate into adipocytes instead of osteoblasts, and not just a 
compensatory filling of space in the absence of bone.(151) Accordingly, osteoporosis in 
older individuals is associated with increased marrow fat and greater efficiency of BM-
MSC differentiation into adipocytes.(150,152) Basal levels of adipogenic genes are higher in 
BM-MSCs derived from older (20 month-old) mice compared to younger (6 month-old) 
mice, as are levels of PPARγ2 mRNA.(148) Older animals are therefore more sensitive to 
PPARγ-mediated suppression of bone formation, and inappropriate activation of PPARγ 
results in an aged-like phenotype.(75,150) Female mice also appear to be more susceptible 
to marrow adiposity, and BM-MSC cultures derived from female mice show an increased 
adipogenic response to a PPARγ agonist (rosiglitazone).(153) Thus, this combination 
makes older individuals more at risk for the side effects of thiazolidinedione anti-diabetic 
drugs (and putative environmental chemicals) that activate PPARγ. 
 
Sexual dimorphism in bone due to hormonal effects 
The steroid hormones estrogen and androgens (e.g. testosterone) play major roles 
in bone homeostasis as well, and varied levels of these hormones between males and 
females have consequences for long-term bone remodeling. The importance of estrogen 
loss in post-menopausal osteoporosis has been hypothesized for many decades,(154) and 
indeed many of the experimental studies assessing the role of estrogen and the estrogen 
receptor characterize functional losses of estrogen signaling and the subsequent 
promotion of bone loss. Although these hormones have indirect effects on bone that are 
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mediated by other organ systems, only direct effects on bone turnover are discussed here. 
The major effect of estrogen in bone is a slowing of remodeling, which in turn 
slows the net resorptive effect of remodeling that occurs in aging bone. This mechanism 
has been demonstrated by loss-of-estrogen models that show simultaneous increases in 
osteoclast and osteoblast precursors.(155) Estrogen levels are negatively correlated with 
levels of RANKL expression on BM-MSCs,(156) and estrogen upregulates OPG.(157) Thus, 
suppression of osteoclast differentiation can be accomplished by decreasing the 
RANKL:OPG ratio in osteoblasts.  
Steroid hormones prolong the lifespan of mature osteoblasts(158) and can help 
maintain trabecular bone density.(143) Interestingly, the estrogen receptor has estrogen-
dependent and estrogen-independent effects on bone. Independent of its ligand, the 
estrogen receptor itself is essential in osteoblast-mediated periosteal bone formation, 
where it stimulates canonical Wnt pathways in osteogenesis.(159) On the other hand, 
estradiol-liganded estrogen receptor can inhibit Wnt signaling and attenuate 
osteoblastogenesis,(159,160) consistent with an overall suppression of bone remodeling.  
Orchidectomy in rats causes increased bone turnover and bone loss that can be 
ameliorated by testosterone treatment,(161) and inactivation of the androgen receptor 
specifically in osteoblasts results in a decrease in trabecular structure.(162,163) More 
precisely, the role of the activated androgen receptor appears to be to support periosteal 
growth in differentiating – rather than mature and mineralizing – osteoblasts.(162) 
Androgens also suppress RANKL (in vitro),(164) but suppress OPG as well.(165) Thus the 
effect of androgens on bone is largely pro-osteoblastic in nature and serves to maintain 
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mineral content and osteoblast population. 
Because of these sex- and age-linked differences, parsing the interplay of 
mechanisms in bone remodeling requires careful consideration of the appropriate 
experimental model, and it is often difficult to hypothesize as to the full suite of effects 
that lead to an observed phenotype if the physiologic state of the animal is not controlled 
for. For instance, the use of an immature mouse model may allow for observations to be 
made on the effects of toxicant exposure on bone apposition that decrease peak bone 
mass; mature mice may be used to study the effects of increased bone resorption, 
particularly in the context of ovariectomy where the influence of estrogen is removed. 
The sensitivity of a toxicant’s effect may differ between males and females, and certain 
phenotypes may only be observed in light of sex-specific background phenotypes.  
Regardless of the model, the tight communication within the remodeling 
environment indicates that perturbation of one factor may lead to dynamic instability of 
numerous other factors to upset the formation/resorption balance. It is in this context that 
we study the effect of bone toxicants as adverse agents that act to not simply suppress or 
stimulate one cell type, but rather to unbalance a dynamic system.  
 
Environmental bone toxicants 
The complex process of bone cell differentiation and communication provides a 
number of targets for toxicants to adversely affect bone homeostasis. Several different 
groups of chemicals provide examples of both naturally occurring and anthropogenic 
compounds that have toxic mechanisms in bone. 
23 
 
 
Lead 
Lead (Pb) has long been known to impact skeletal development. Because of a 
chemical similarity to calcium, lead persists in the body by accumulating in bone 
(particularly trabecular bone),(166,167) where its half-life is estimated to be 10–30 years.(83) 
Because lead is so preferentially distributed to this tissue (accounting for ~95% of the 
lead body burden),(83) cumulative lead exposure metrics typically involve non-invasive 
measurements of bone lead rather than circulating blood lead levels. However, during 
periods of high calcium demand, such as pregnancy, lactation or menopause,(166,168–170) 
bone is resorbed and lead is mobilized into the blood.(171) Under these conditions, inverse 
associations between blood lead levels and bone mineral density have been found.(166) 
Mechanistically, lead exposure has been tied to suppression of osteoblast 
differentiation and activity, and subsequent impairment of bone formation.(172,173) This is 
accomplished by an upregulation of sclerostin and suppression of Wnt signaling, leading 
to an increase in adipogenesis in the bone marrow.(174,175) Lead also suppresses the 
response to osteogenic stimulation factors such as vitamin D and insulin-like growth 
factor (IGF-1).(176) Interestingly, lead also has been shown to upregulate aryl hydrocarbon 
receptor (AHR, discussed below) expression in osteoblasts, potentially increasing their 
sensitivity to xenobiotics.(177) Ultimately, lead exposure reduces overall bone mass,(174) 
leading to associations with decreases in skeletal growth that have been observed in 
epidemiologic studies.(178,179) On the contrary, recent experimental data in a mouse model 
have shown increases in bone volume early in life owing to a lead-induced suppression of 
osteoclast resorptive activity.(180)  
24 
 
 
Arsenic 
Epidemiologic studies of arsenic (As) toxicity have not typically focused on 
specific bone structural outcomes, but rather have focused on developmental exposure-
related growth impairment and indirect effects related to bone.(181) In its inorganic 
speciation, arsenic replaces phosphate in bone,(182) and the toxic effects of inorganic 
arsenic on the bone marrow leading to anemia are well established.(183)  
In vivo, arsenic exhibits a toxic effect on osteoblasts in rodent models where the 
exposure mimics human drinking water exposure.(184) The phenotype resulting from this 
exposure was characterized by decreases in bone mineral density, trabecular volume, and 
cortical thickness in the tibia. This was shown to be related to suppression of Runx2 in 
osteoblasts via upregulation of a specific kinase activity (shown independently to 
suppress Runx2)(184) and activation of oxidative stress pathways.(185) In an in vitro 
osteoclast model, inorganic arsenic induced differentiation of osteoclasts at 
concentrations comparable to those observed in human biomonitoring, suggesting that 
arsenic exposure could contribute to the current prevalence of low bone density 
disorders.(186)  
 
Cadmium 
One of the earliest connections between cadmium (Cd) and bone disease was 
found among a Japanese cohort in 1950’s suffering from itai-itai disease, a bone 
pathology characterized in part by brittle and weak bones. Incidence of this disease was 
linked to consumption of cadmium-contaminated rice.(187) Although in this case 
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cadmium’s critical target was the kidney, where high exposures altered vitamin D 
metabolism and indirectly affected bone homeostasis, low levels of cadmium exposure 
have recently been associated with low bone density and risk of osteoporosis, and animal 
models have established that cadmium can act directly on bone to induce bone loss.(188–
190)  
Cell culture models have shown that cadmium can act on both osteoblasts and 
osteoclasts, but at different dose ranges. For instance, at higher (micromolar) 
concentrations, cadmium suppresses osteoblast activity, indicated by decreases in 
alkaline phosphatase activity and decreased nodule formation.(190) At nanomolar 
concentrations, cadmium stimulates the differentiation and resorptive function of 
osteoclasts directly.(191) Thus, cadmium is mechanistically capable of perturbing the 
normal differentiation and function of both cell types, as well as their communication, in 
a manner consistent with a net loss of bone.  
 
Tungsten 
Tungsten (W) can accumulate and persist in bone,(192,193) though it has only 
recently been investigated as a bone toxicant.(194) In vivo, tungsten does not appear to 
suppress osteogenesis, but it does increase bone marrow adipocyte content specifically in 
younger male mice, a difference partially attributed to a lower baseline level of adipocyte 
content in males. It is hypothesized that bone turnover facilitates accumulation of 
tungsten in bone, as older male and female mice had substantially lowered tungsten 
concentrations following exposure.(194)  
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Interestingly, tungsten alone does not increase adipogenesis in in vitro BM-MSC 
cultures, but it does enhance PPARγ-mediated adipogenesis.(194) This suggests that 
tungsten’s target molecule is upstream of PPARγ activation. Thus, co-exposures to 
tungsten and PPARγ-activating compounds – a plausible scenario given tungsten’s use in 
implanted medical devices(195) –  could potentially exacerbate age-related bone loss.    
 
Ethanol 
Ethanol may not strictly fit the definition of environmental toxicant inasmuch as 
exposure is typically intentional rather than inadvertent, but given the prevalence of 
alcohol use it remains and important toxicant of note. The toxicity of ethanol to the 
skeleton is somewhat underappreciated, particularly in skeletally vulnerable populations 
such as women post-pregnancy,(196) though it is well-recognized that chronic alcoholism 
is associated with osteoporosis and risk of fracture.(197) This loss of bone has been 
attributed to both inhibition of bone formation and increases in bone resorption.  
The central mechanism associated with ethanol’s effect on bone cells is oxidative 
stress. Several models have shown that ethanol-induced oxidative stress effectively 
inhibits Wnt signaling in mesenchymal stromal cells,(196) which is accompanied by a 
reciprocal increase in PPARγ-mediated suppression of osteoblast differentiation. This can 
be reversed with antioxidant treatment(196) as well as estrogen.(198) Reactive oxygen 
species generated by ethanol’s mechanism of action in mature osteoblasts increases 
RANKL expression, hence increased osteoclastogenesis in alcohol-exposed animals.(199)  
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Polycyclic Aromatic Hydrocarbons (PAHs) 
PAHs are a class of chemicals generated from incomplete combustion and for 
industrial manufacturing uses. Many of the toxic effects of PAHs are mediated by the 
aryl hydrocarbon receptor (AHR), which is expressed in both osteoclasts(200) and 
osteoblasts,(177) and much of the research on AHR-mediated bone effects has been driven 
by the observation that cigarette smoking (a significant source of PAHs) is a risk factor 
for low bone density.(201) 
For example, benzo[a]pyrene (BaP) and 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD), both found in cigarette smoke, increase osteoclastogenesis and bone resorption 
through a mechanism involving characteristic Cyp1 enzyme induction by AHR 
activation.(202) However, it is not known as to how Cyp1 enzymes are sufficient to 
stimulate osteoclast differentiation. Osteoclast-specific AHR knockout models show 
resistance to ovariectomy-induced bone loss, establishing the importance of AHR in 
osteoclast function and overall bone homeostasis.(203) Osteoblasts are also sensitive to 
AHR-mediated effects on differentiation, as concentrations of TCDD as low as 100 
femtomolar are sufficient to suppress expression of alkaline phosphatase (Alp) and the 
maturation marker osteocalcin (Ocn).(204)  
It is clear from these examples that bone homeostasis is sensitive to exogenous 
stimuli, and a large variety of environmental chemicals can impact bone health via 
different mechanisms. The general thesis of this dissertation is that environmental 
chemicals can adversely affect bone homeostasis by activating nuclear receptors in bone 
cells to perturb cellular differentiation and function. Three studies are presented: the first 
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two studies (Chapters II and III) investigate mechanisms of nuclear receptor-mediated 
toxicity in bone, with an emphasis on PPARγ:RXRα activation, using in vitro and in vivo 
approaches. The third study (Chapter IV) characterizes approaches to predicting 
combinatorial effects of PPARγ ligands in complex mixtures. Last, Chapter V describes 
limitations and future directions of each study, and suggests implications of this work for 
public health in general. 
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Abstract  
 
Environmental obesogens are a newly recognized category of endocrine disrupting 
chemicals that have been implicated in contributing to the rising rates of obesity in the 
United States.  While obesity is typically regarded as an increase in visceral fat, adipocyte 
accumulation in the bone has been linked to increased fracture risk, lower bone density, 
and osteoporosis.  Exposure to environmental toxicants that activate peroxisome 
proliferator activated receptor γ (PPARγ), a critical regulator of the balance of 
differentiation between adipogenesis and osteogenesis, may contribute to the increasing 
prevalence of osteoporosis.  However, induction of adipogenesis and suppression of 
osteogenesis are separable activities of PPARγ, and ligands may selectively alter these 
activities.  It currently is unknown whether suppression of osteogenesis is a common 
toxic endpoint of environmental PPARγ ligands. Using a primary mouse bone marrow 
culture model, we tested the hypothesis that environmental toxicants acting as PPARγ 
agonists divert the differentiation pathway of bone marrow-derived multipotent 
mesenchymal stromal cells towards adipogenesis and away from osteogenesis.  The 
toxicants tested included the organotins tributyltin and triphenyltin, a ubiquitous 
phthalate metabolite (mono-(2-ethylhexyl) phthalate, MEHP), and two brominated flame 
retardants (tetrabromobisphenol-a, TBBPA, and mono-(2-ethylhexyl) 
tetrabromophthalate, METBP).  All of the compounds activated PPARγ1 and 2. All 
compounds increased adipogenesis (lipid accumulation, Fabp4 expression) and 
suppressed osteogenesis (alkaline phosphatase activity, Osx expression) in mouse 
primary bone marrow cultures, but with different potencies and efficacies. Despite 
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structural dissimilarities, there was a strong negative correlation between efficacies to 
induce adipogenesis and suppress osteogenesis, with the organotins being distinct in their 
exceptional ability to suppress osteogenesis. As human exposure to a mixture of toxicants 
is likely, albeit at low doses, the fact that multiple toxicants are capable of suppressing 
bone formation supports the hypothesis that environmental PPARγ ligands represent an 
emerging threat to human bone health. 
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Introduction  
The bone marrow is a specialized microenvironment containing both bone and 
adipose cells.  Because the bone tissue is undergoing near constant homeostatic 
remodeling, any perturbation in the balance of adipogenesis and osteogenesis could lead 
to alterations in bone maintenance.  Bone ageing is associated with increased adiposity, 
reduced osteoblast function, and increased osteoclast activity, giving rise to osteoporotic 
pathologies such as reduced bone mass, altered bone structure, and increased risk of 
fracture.(150) Bone loss that occurs with aging also is associated with an increase in 
peroxisome proliferator active receptor γ (PPARγ) expression in the marrow.(148)  
The plasticity of bone marrow multipotent mesenchymal stromal cells (BM-
MSCs) allows them to differentiate into either adipocytes or osteocytes.  Adipocyte 
formation is dependent on PPARγ activation(27) whereas bone formation is chiefly 
controlled by runt related transcription factor 2 (Runx2).(95)  MSC differentiation is 
controlled by the balance of PPARγ and Runx2 transcriptional activation and co-
regulated by signaling through the Wnt/β-catenin pathway, which modulates the 
expression and function of both PPARγ and Runx2.(96,97,100,205)  
Activation of PPARγ by the therapeutic ligand rosiglitazone drives differentiation 
toward adipogenesis and suppresses osteogenesis, a result observed both in vitro and in 
vivo.(15,74) Conversely, decreasing expression of PPARγ (e.g. by molecular knockdown) 
results in reduced adipogenesis and increased bone mass.(16) Human treatment with 
therapeutic PPARγ ligands (e.g. thiazolidinediones) is associated with an increased risk 
of fracture in bone.(206–208)   
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While there is a reciprocal relationship between bone formation and adipogenesis 
in response to PPARγ activation by rosiglitazone, these functions of PPARγ (along with 
insulin sensitization) are distinct and separable. For example, Rahman et al. (2012) 
demonstrated the anti-osteogenic capability of PPARγ to be independent of its pro-
adipogenic activity.(209) Phosphorylation of PPARγ can increase insulin sensitivity 
independently of adipogenesis.(210) PPARγ ligands can selectively activate the multiples 
functions of PPARγ, with the distinct abilities to activate adipogenesis and suppress 
osteogenesis not necessarily being correlated.(73,211,212)  
A growing number of environmental contaminants, including organotins and 
phthalates, are being recognized for their ability to activate PPARγ and therefore are 
members of the environmental obesogen class of toxicants.(57)  While organotins 
primarily have been used as antifouling agents and fungicides, their pervasive distribution 
is indicated by their presence in house dust.(213)  Significant human exposure is indicated 
by the presence of organotins in liver and blood (0.1–450 nM).(214)  Despite being 
structurally distinct from several other PPARγ ligands, multiple organotins are capable of 
activating PPARγ and its heterodimerization partner, retinoid X receptor, and act as 
potent and efficacious adipogenic agents in pre-adipocyte and MSC models.(59,80,82) 
Phthalates are well-known environmental PPARγ ligands.(51,64)  Over 18 billion 
pounds of phthalates are produced yearly, and humans are regularly exposed to 
significant levels (~10 μg/kg bw/day) of di-(2-ethylhexyl) phthalate (DEHP).(215)  
Substantial exposures occur during acute medical procedures, resulting in blood DEHP 
concentrations ranging from 50–350 μM.(216)  MEHP, the active metabolite of DEHP, 
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directly activates PPARγ and promotes adipogenesis in NIH 3T3L1 cells(51,64,65) and has 
been measured in human blood samples at μM concentrations.(217)   
Newly recognized environmental PPARγ ligands include tetrabromobisphenol-A 
(TBBPA)(67) and mono-(2-ethylhexyl)tetrabromophthalate (METBP)(66). TBBPA is a 
component of the mass produced brominated flame retardants (over 150,000 tons 
annually),(218) is detectable in home and office dust samples,(219,220) and in human breast 
milk and serum (at levels as high as 649 ng/g lipid weight).(221) Di-(2-
ethylhexyl)tetrabromophthalate, a component of Firemaster® 550, has been found at ppm 
levels in house dust and at 260 ng/g lipid weight in humans,(222) and its metabolite 
METBP is capable of increasing lipid accumulation as well as activating expression of 
the PPARγ gene target fatty acid binding protein 4 (Fabp4) in NIH 3T3-L1 cells.(66)   
PPARγ-mediated suppression of bone formation and the substantial human 
exposure to multiple environmental PPARγ ligands highlight the need to understand their 
contribution to bone loss.  Furthermore, it is unknown if the pro-adipogenic effects of 
these environmental PPARγ ligands are associated with or are distinct from anti-
osteogenic effects, an important question because divergent effects have been shown for 
some natural and synthetic ligands.(73,211,212) Studies described herein were designed to 
test the hypothesis that environmental PPARγ ligands, in general, selectively induce 
adipogenesis at the expense of osteogenesis.  Accordingly, we examined the potential for 
a structurally diverse set of environmental PPARγ ligands (TPhT, MEHP, TBBPA, 
METBP) to induce adipogenesis and suppress osteogenesis in mouse-derived bone 
marrow MSCs (BM-MSCs) in comparison to PPARγ ligands known to suppress bone 
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formation (rosiglitazone and tributyltin (TBT)).  Surprisingly, despite the structural 
dissimilarities of the ligands, the efficacy of osteogenesis suppression by treatment was 
strongly negatively correlated with efficacy of induction of adipogenesis.  The organotins 
were distinct in their exceptional ability to suppress osteogenesis.  The data are consistent 
with the conclusion that suppression of osteogenesis is a common toxic effect of 
environmental toxicants that are capable of activating PPARγ. 
 
Materials and Methods 
Materials  
Rosiglitazone was from Cayman Chemical (Ann Arbor, MI).  DMSO was from 
American Bioanalytical (Natick, MA).  Insulin, Nile Red, p-nitrophenyl phosphate 
(pNPP) reagent, TBT chloride, TPhT chloride, and TBBPA were from Sigma-Aldrich 
(St. Louis, MO).  MEHP was from TCI America (Portland, OR).  METBP was 
synthesized by AsisChem (Waltham, MA).  All other reagents were from Thermo Fisher 
Scientific (Suwanee, GA). 
 
Cell culture  
 Bone marrow was isolated from 9-week-old male C57BL/6J mice (Jackson 
Laboratories, Bar Harbor, ME).  All animal studies were reviewed and approved by the 
Institutional Animal Care and Use Committee at Boston University.  All animals were 
treated humanely and with regard for alleviation of suffering.  Mice were housed 4 per 
cage, with a 12 hour light cycle. Water and food (2018 Teklad Global 18% Protein 
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Rodent Diet, Irradiated, Harlan Laboratories, Indianapolis, IN) were provided ad libitum. 
Animals were euthanized for collection of bone marrow two days after arrival. After 
euthanasia (cervical dislocation under terminal euthanasia followed by pneumothorax), 
limbs were aseptically dissected, and soft tissue was removed from the bone. Marrow 
was flushed from the femur, humerus, and tibia bones, strained through a 70 um cell 
strainer, and suspended in MSC medium consisting of α-MEM, 10% fetal bovine serum, 
100 U/ml penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml amphotericin-B.  Cells 
from 2–4 animals were pooled and plated so that each pool represented an experimental 
n.  Cells were plated either in 6-well (12 million cells in 2 mls per well) or 12-well plates 
(6 million cells in 1 ml per well).  Half of the medium was replaced 5 days after plating.  
At day 7, the medium was replaced with osteoinductive medium consisting of α-MEM, 
12.5 μg/ml l-ascorbate, 8 mM β-glycerol phosphate, 0.5 μg/ml insulin, and 10 nM 
dexamethasone.  Prior to the day 7 medium change, a naïve, undifferentiated well was 
harvested for gene expression analysis as described below.  Cells received no treatment 
(Naïve) or were dosed with vehicle (DMSO, 0.1% final concentration) or with the 
chemical of interest.  Following treatment, cells were cultured for 7 days (mRNA 
expression) or 10–11 days (adipocyte and bone phenotype, cell viability).  During these 
periods, medium was changed and the cultures were re-dosed 2 times for mRNA 
expression or 3 times for phenotype analysis.   
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Cell viability assay  
Viability was assessed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide (MTT) labeling for 3 hrs by standard methods.  Absorbance measurements were 
determined using a Synergy2 plate reader (BioTek, Winooski, VT).  Absorbance in 
experimental wells was normalized by dividing by the absorbance in untreated cultures 
and reported as “Fold Change from Medium.” 
 
Lipid accumulation 
Cells were washed with one volume of PBS and incubated with Nile Red (1 μg/ml 
in PBS).  Fluorescence (excitation 485 nm, 20 nm bandwidth; emission 530 nm, 25 nm 
bandwidth) was measured using a Synergy2 plate reader.  The fluorescence in all 
experimental wells was normalized by subtracting the fluorescence measured in Naïve 
cells (those that received osteogenic medium alone) and reported as “RFUs.” 
 
Osteogenesis assays 
Following Nile Red staining, cells were rinsed with PBS and fixed in 
paraformaldehyde (2% in PBS).  To quantify alkaline phosphatase activity, cells were 
incubated in pNPP solution.  After quenching with NaOH (final concentration: 0.75M), 
absorbance (405 nM) was measured using a Synergy2 multifunction plate reader.  The 
absorbance in all experimental wells was normalized by dividing by the absorbance 
measured in wells that received osteogenic medium but were not treated and reported as 
“Fold Change from Medium.” Following the pNPP assay, cells were stained with 
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Alizarin Red (Osteogenesis Quantitation Kit, Millipore, Billerica, MA).  Cells were 
extensively washed and then photographed using the UVP Bioimaging System (UVP, 
Inc., Upland, CA).  The resulting images were analyzed for bone nodule count using 
Image-Pro Plus (MediaCybernetics, Bethesda, MD), and the number of nodules per 
square cm is reported.  Following image capture, Alizarin Red staining was quantified as 
indicated in the manufacturer’s instructions.  Absorbance (405 nM) was measured and 
normalized as described above. 
 
Gene expression analysis 
Total RNA was extracted and genomic DNA was removed using the RNeasy Plus 
Mini Kit (Qiagen, Valencia, CA).  cDNA was prepared from total RNA using the 
GoScript™ Reverse Transcription System (Promega), with a 1:1 mixture of random and 
Oligo (dT)15 primers.  All qPCR reactions were performed using the GoTaq® qPCR 
Master Mix System (Promega).  Validated primers were purchased from Qiagen (see 
Supplemental Table 1).  qPCR reactions (in duplicate) were performed using a 7300 Fast 
Real-Time PCR System (Applied Biosystems, Carlsbad, CA): Hot-Start activation at 
95°C for 2 min, 40 cycles of denaturation (95°C for 15 sec) and annealing/extension 
(55°C for 60 sec).  Relative gene expression was determined using the Pfaffl method to 
account for differential primer efficiencies.(223)  The Cq value for 18s ribosomal RNA 
(Rn18s) was used for normalization.  The Cq value for naïve, undifferentiated cultures 
was used as the reference point, and the data are reported as “Fold Change from Naive.”   
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Protein expression 
Cells were collected and lysed in Cell Lysis Buffer (Cell Signaling Technology, 
Beverly, MA) followed by sonication.  The lysates were cleared by centrifugation, and 
the supernatants were used for protein expression analyses.  Protein concentrations were 
determined by the Bradford method.  Total proteins (20 µg) were resolved on 10% 
polyacrylamide gels, transferred to a 0.2 µm nitrocellulose membrane, and incubated 
with monoclonal rabbit anti-perilipin (3470, Cell Signaling Technology (Beverly, MA)).  
Immunoreactive bands were detected using HRP-conjugated goat-anti rabbit secondary 
antibodies (Biorad, Hercules, CA) followed by enhanced chemiluminescence. To control 
for equal protein loading, blots were re-probed with a β-actin-specific antibody (A5441, 
Sigma). 
 
Reporter assays 
Cos-7 cells (in 96 well plates) were transiently transfected with vectors containing mouse 
Pparg1 (plasmid 8886; Addgene, Cambridge, MA) or mouse Pparg2 (plasmid 8862; 
Addgene), with human RXRA (plasmid 8882; Addgene),(27) PPRE x3-TK-luc (plasmid 
1015; Addgene),(224) and CMV-eGFP using Lipofectamine 2000 (Invitrogen, Carlsbad, 
CA).  Transfected cultures were incubated overnight.  The medium was replaced, and 
cultures received no treatment (Naïve) or were treated with Vh (DMSO, 0.1%), 
rosiglitazone, TBT, TPhT, METBP, MEHP, TBBPA at concentrations ranging from 0.1 
nM to 400μM and incubated for 24 hrs.  Cells were lysed in Glo Lysis Buffer (Promega, 
Madison, WI), to which Bright Glo Reagent (Promega) was added.  Luminescence and 
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fluorescence were determined using a Synergy2 plate reader.  Luminescence was 
normalized by the GFP fluorescence in the same well.  The normalized luminescence for 
each well was then divided by the normalized luminescence measured in transfected but 
untreated wells to determine the “Fold Change from Naive.” 
 
Statistical Analyses 
 Statistical analyses were performed with Prism 5 (GraphPad SoftwareInc., La 
Jolla, CA).  Data are presented as means  standard error (SE).  Gene expression data 
were log transformed prior to analysis.  One-way ANOVAs with the Dunnett’s post hoc 
test and Pearson’s correlations were performed where noted.  All analyses were 
performed at α = 0.05.   
 
Results 
Activation of PPARγ1 and PPARγ2  
 Whereas each of the toxicants being investigated in this study has been identified 
as a PPARγ ligand, they have not been characterized for their potency and efficacy all in 
the same study.  Thus, we began by characterizing the dose-response of each individual 
ligand with respect to activation of mouse PPARγ1 and PPARγ2 using a PPRE-luciferase 
reporter in Cos-7 cells (Fig. 2.1).  Curve maxima, EC50s, and Hill coefficients are 
reported in Table 1.  Rosiglitazone, the positive control, was potent and efficacious at 
activating PPARγ1 and 2.  The organotins, TBT and TPhT, had similar potencies and 
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efficacies as rosiglitazone.  MEHP, TBBPA, and METBP each acted as partial agonists, 
with lower efficacies and potencies compared to rosiglitazone.   
 
Induction of adipogenesis in bone marrow derived MSCs 
 Our studies and others have demonstrated that both rosiglitazone and TBT are 
potent inducers of adipogenesis in the mouse-derived bone marrow MSC lines BMS2 and 
U33/γ2, as well as adipose-derived stromal cells.(60,73,80)  Furthermore, rosiglitazone has 
been shown to concurrently suppress osteogenesis as it induces adipogenesis.(15)  Here, 
we tested the hypothesis that environmental PPARγ agonists would divert differentiation 
toward adipogenesis in primary bone marrow MSCs grown in osteogenic conditions.  
 We established the maximal adipogenic response in our system using two known 
differentiation modulators, rosiglitazone and TBT.  Primary bone marrow cultures were 
prepared from male C57BL/6J mice and treated with Vh (DMSO, 0.1%), TBT (100 nM), 
or rosiglitazone (100 nM) in the presence of osteoinductive medium.  Cultures were 
assessed for lipid accumulation (10–12 days) and adipogenic gene expression (7 days).  
As expected, TBT and rosiglitazone induced significant lipid accumulation compared to 
Vh-treated cells (Fig. 2.2a), although TBT was less efficacious than rosiglitazone.  
Whereas TBT and rosiglitazone did not induce expression of Pparg1/2, they strongly 
induced its target genes Fabp4 and perilipin (Plin1) (Fig. 2.2b–2.2d).  
Next, we tested the ability of several structurally distinct environmental PPARγ 
ligands to induce adipogenesis in BM-MSCs. Established bone marrow cultures were 
treated with Vh (DMSO, 0.1%), TPhT (10, 50, 80 nM), MEHP, METBP or TBBPA (10, 
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20 μM), in the presence of osteoinductive medium.  The high concentration in each case 
was the maximal sub-toxic concentration in this model (Supplemental Fig. 2.1).  At all 
concentrations, TPhT significantly increased lipid accumulation compared to Vh-treated 
cells, with an efficacy similar to 100 nM TBT (Fig. 2.3a).  While there was only a trend 
toward an increase in expression of Pparg1/2 mRNA, expression of the PPARγ target 
genes Fabp4 and Plin1 was increased significantly by all concentrations of TPhT (Fig. 
2.3a).  A similar pattern of effect was observed with MEHP and TBBPA, with significant 
increases occurring in lipid accumulation and PPARγ-target gene expression (Fig. 2.3b 
and 2.3d).  METBP showed more limited increases in lipid accumulation, Fabp4 
expression and Plin1 expression (Fig. 2.3c). 
Terminal adipocyte differentiation was confirmed by analyzing perilipin protein 
expression.  Established cultures were treated with Vh (DMSO, 0.1%), rosiglitazone (100 
nM), TBT (100 nM), TPhT (50 nM), MEHP, TBBPA or METBP (20 μM each), in the 
presence of osteoinductive medium for 7 days.  All of the chemicals induced the 
expression of perilipin protein (Fig. 2.4).  Rosiglitazone alone induced formation of 
multiple bands.  Perilipin is a phosphoprotein, thus the multiple bands observed are likely 
phosphorylated and non-phosphorylated forms of the protein.(225)   
These data illustrate that structurally diverse environmental PPARγ ligands 
induce adipocyte differentiation and PPARγ signaling in primary bone marrow MSCs, 
but with different potencies and efficacies.   
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Environmental PPARγ ligands show differential efficacies of bone suppression in 
primary bone marrow MSCs 
A number of studies have demonstrated that therapeutic PPARγ agonists suppress 
osteoblast differentiation and bone formation both in vitro(15,96) and in vivo.(74,75)  
Similarly, TBT inhibits differentiation of osteoblast-like (ROB) cells(226) and suppresses 
osteogenesis in multipotent adipose-derived stromal cells by a PPARγ-mediated 
mechanism.(60)  Here, we tested the hypothesis that environmental PPARγ-agonists would 
suppress osteogenic differentiation in BM-MSCs.  
Again, we began by establishing the effect of rosiglitazone and TBT in our model 
system.  Primary bone marrow cultures were prepared from male C57BL/6J mice and 
treated with Vh (DMSO, 0.1%), TBT (100 nM), or rosiglitazone (100 nM) in the 
presence of osteoinductive medium.  Cultures were assessed for changes in alkaline 
phosphatase activity, mineralization, and nodule number (10–12 days) and osteogenic 
gene expression (7 days).  Both TBT and rosiglitazone significantly decreased alkaline 
phosphatase activity and the average number of bone nodules per square cm (Fig. 2.5a).  
TBT also significantly suppressed calcium deposition (Fig. 2.5a).  Suppression of 
osteogenesis also was reflected in decreased expression of osteogenic genes (Fig. 2.5b).  
TBT and rosiglitazone significantly suppressed expression of Runx2, an essential 
transcription factor regulating osteogenesis, as well as expression of osterix (Osx), a 
direct gene target of Runx2 (Fig. 2.4b).  Only TBT significantly suppressed expression of 
dentin matrix phosphoprotein 1 (Dmp1), a gene expressed in mineralizing osteocytes.(102)   
Next, we tested the ability of the environmental PPARγ ligands to suppress 
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osteogenesis. Established bone marrow cultures were treated with Vh (DMSO, 0.1%), 
TPhT (10, 50, 80 nM), MEHP, TBBPA or METBP (10, 20 μM), in the presence of 
osteoinductive medium.  A concentration of TPhT as low as 10 nM significantly 
decreased alkaline phosphatase activity, nodule number, and mineralization (Fig. 2.6a).  
The other ligands were less efficacious at suppressing osteogenesis.  MEHP, METBP and 
TBBPA significantly suppressed alkaline phosphatase activity, but only MEHP 
significantly suppressed nodule number (Fig. 2.6b–2.6d).  The treatment regimen and 
concentrations did not reduce cellularity as measured by MTT labeling (Supplemental 
Fig. 2.1), indicating that the effect of the ligands was specific and not the result of overt 
toxicity. 
Decreases in the expression of osteoblast/osteocyte-related genes accompanied 
suppression of osteogenesis (Fig. 2.7).  Runx2 expression was relatively resistant to 
toxicant exposure and was only reduced by treatment with MEHP and TBBPA (Fig. 2.7b 
and 2.7d).  Osx expression was the most sensitive, with all toxicants significantly 
reducing expression and TPhT, MEHP, and TBBPA reducing Osx expression at the 
lowest concentration (Fig. 2.7a, 2.7b and 2.7d). TPhT and MEHP also significantly 
reduced Dmp1 expression (Fig. 2.7a and 2.7b).  As with the phenotypic assays, METBP 
had a limited capacity to suppress osteoblast-related gene expression (Fig. 2.7d).   
The data support the conclusion that suppression of osteogenesis is a common 
toxic effect of environmental toxicants that are capable of activating PPARγ. 
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Effects on adipogenesis and osteogenesis are negatively correlated 
 A balance of transcriptional activity determines the fate of MSCs, with PPARγ 
promoting adipogenesis and negatively regulating Runx2, and Runx2 promoting 
osteogenesis following Wnt/β-catenin suppression of PPARγ.(97)  Thus, differentiation of 
MSCs has traditionally been viewed as either exclusively toward adipogenesis or 
exclusively toward osteogenesis.  Despite the fact that the PPARγ ligands tested here 
vary widely in their structure, as well as their potency and efficacy for inducing 
adipogenesis, they demonstrate strong, significant relationships (p < 0.05, Pearson’s r, 
excluding organotins) between efficacy of induction of adipogenesis and efficacy of 
suppression of osteogenesis (Fig. 2.8a–2.8c).  However, the organotins appear to be more 
efficacious at suppressing bone formation than the other toxicants. We hypothesize that 
this is because they are dual RXR and PPARγ ligands, thus they were removed from the 
correlation analysis, and this greatly improved the correlation.  In general, these data 
support the conclusion that suppression of osteogenesis accompanies induction of 
adipogenesis by multiple environmental PPARγ ligands. However, the relationship of the 
efficacies of the effects may be ligand-specific.  
 
The disproportionate effect of organotins is not mediated by Wnt10b 
Recently, Rahman et al. (2012) found that the adipogenic effects of PPARγ 
activation are “sequestered” via β-catenin suppression, while the anti-osteogenic capacity 
of PPARγ is maintained through suppression of wingless-type MMTV integration site 
family, member 10b (Wnt10b), a secreted protein that activates the canonical Wnt-
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signaling pathway of osteogenesis. Stabilization of β-catenin suppressed PPARγ-
mediated adipogenic effects, but PPARγ-dependent suppression of Wnt10b was 
maintained and resulted in an anti-osteogenic phenotype.(209) Given that our experiments 
suggest a disproportionate effect of osteogenic suppression by the organotins, we 
hypothesized that cells treated with organotins would show a disproportionate 
suppression of Wnt10b RNA expression compared to rosiglitazone and MEHP.   
 To test this hypothesis, we examined the expression of Wnt10b mRNA in 
osteogenic cultures treated with Vh (DMSO, 0.1%), rosiglitazone (100 nM), TBT (100 
nM), TPhT (10, 50, and 80 nM) or MEHP (10 and 20 μM) for 7 days.  Rosiglitazone was 
the only ligand that significantly suppressed the expression of Wnt10b mRNA (Fig. 2.9a), 
supporting the observation reported by Rahman et al. (2012) and Lecka-Czernik et al. 
(2002).(73,209) However, neither TBT nor TPhT significantly reduced Wnt10b expression 
(Figs. 2.9a and 2.9b), and the Wnt10b expression level was not qualitatively different 
from the Wnt10b expression in MEHP-treated cultures (Fig 2.9c). Thus, the data do not 
support a role for disproportionate effects on Wnt10b in organotin-induced suppression of 
osteogenesis.  
 
Discussion 
 47 million individuals in the U.S. are estimated to be at risk for osteoporosis by 
2020, representing a major public health concern among the aging U.S. population.(227)  
Accordingly, it is important to understand the factors that contribute to low bone density, 
a significant risk factor for osteoporosis. Because precursor bone marrow cells are 
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capable of differentiation into pre-osteocytes or pre-adipocytes, a shift towards adipocyte 
differentiation instead of osteocyte differentiation could have deleterious effects on bone 
health.  In fact, increases in lipid accumulation are associated with greater fracture risk 
and the onset of osteoporosis (for review, see Rosen and Bouxsein (2006)),(150) and 
treatment with therapeutic PPARγ ligands is associated with greater fracture risk among 
diabetics.(206) We hypothesized that environmental PPARγ ligands would promote 
differentiation of BM-MSCs into adipocytes at the expense of differentiation into 
osteocytes and bone formation.    
 A growing number of environmental toxicants have been identified as PPARγ 
ligands whose diversity of sources and high-volume production result in significant 
human exposures.  Here, we examined the potency and efficacy of TBT, TPhT, MEHP, 
METBP, and TBBPA in activation of mouse PPARγ1 and PPARγ2 and then examined 
their pro-adipogenic and anti-osteogenic effects in mouse BM-MSCs.  All of the 
toxicants tested activated both mPPARγ1 and γ2, with the rank potency of 
Rosiglitazone=TBT=TPhT>>TBBPA>MEHP>METBP.  Their rank efficacy for PPARγ1 
and γ2 activation was Rosiglitazone=TBT=TPhT>MEHP>TBBPA= METBP.  MEHP, 
METBP and TBBPA were apparent partial agonists of PPARγ with, in the cases of 
MEHP and TBBPA, EC50’s similar to values previously reported.(64,67)  Similar to our 
studies, others have shown TBT and TPhT have similar potency inducing lipid 
accumulation in a multipotent MSC model and for activation of human PPARγ compared 
to rosiglitazone and troglitazone.(58,59,80)  
 The potency of PPARγ activation was largely reflected in each toxicant’s ability 
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to stimulate adipocyte differentiation, as evidenced by lipid accumulation and PPARγ 
target gene expression.  As expected, the potent therapeutic PPARγ ligand rosiglitazone 
was most efficacious at stimulating adipocyte differentiation in BM-MSCs, as has been 
observed in mouse and human models of preadipocytes and multipotent MSCs.(59,60,80,82)  
The organotins, while apparent full agonists in terms of PPARγ transcriptional activation, 
were potent but not fully efficacious at stimulating lipid accumulation and PPARγ target 
gene expression in BM-MSCs.  Our lipid accumulation and PPARγ activation results 
with TBT and TPhT confirm previous results showing sub-maximal efficacy in BMS2 
cells.(80)   
 On the other hand, MEHP was an apparent partial agonist in terms of PPARγ 
transactivation, but efficaciously stimulated lipid accumulation and PPARγ target gene 
expression.  The partial agonist nature of MEHP has been previously reported.(51) In our 
study, MEHP (20 μM, 7–10 days, insulin and dexamethasone) induced lipid 
accumulation in mouse BM-MSCs to an extent comparable to the full agonist 
rosiglitazone, whereas Feige et al. (2007) found that NIH 3T3-L1 cells treated with 
MEHP (100 μM, 10 days, insulin) accumulated lipid (triglyceride content) to only 50% 
of rosiglitazone treatment.(51)  Both rosiglitazone and MEHP efficaciously induced genes 
important to adipogenesis in the BM-MSC and NIH 3T3 L1 models (e.g. Fabp4, Plin1 
(BM-MSCs) and adiponectin (NIH 3T3-L1s)).  However, other PPARγ gene targets (e.g. 
glycerol kinase, oxidized low density lipoprotein receptor 1, acyl-CoA synthetase 
Bubblegum 1) have been shown to only be efficaciously induced by rosiglitazone, mostly 
likely because MEHP selectively recruits coactivators to the PPARγ transcriptional 
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complex.(51)   
 METBP, the metabolite of an emerging environmental contaminant, di-(2-
ethylhexyl) tetrabromophthalate, significantly stimulated lipid accumulation but was less 
efficacious at stimulating PPARγ-target gene expression, in line with its marginal ability 
to stimulate PPARγ transcriptional activity.  These results are in accordance with a recent 
study showing that METBP induced adipocyte differentiation and PPARγ activation in 
NIH 3T3 L1 cells.(66)  That METBP should display an adipogenic profile similar to 
MEHP is not entirely surprising, given previous studies showing multiple phthalate 
monoester metabolites activating PPARγ with comparable potencies and efficacies.(64)   
 Like MEHP, TBBPA appears to be a partial ligand of PPARγ with significant but 
not maximal efficacy in inducing adipocyte differentiation.  The receptor activation data 
show that TBBPA is a low-potency PPARγ ligand with moderate efficacy.  This is 
similar to studies conducted in human PPARγ-based reporter cells, where tri- and 
tetrabrominated BPA had the greatest potency and efficacy in activating PPARγ, with 
decreasing substitution significantly decreasing activity.(67)  Our results confirmed the 
ability of TBBPA to induce adipogenesis, accompanied by significant increases in 
Pparg1/2, Fabp4 and Plin1 expression.   
 This is the first report that TPhT, MEHP and TBBPA suppress osteogenesis. We 
expected to find that those environmental toxicants that induced adipogenesis would also 
suppress osteogenesis, owing to the inhibitory interactions between PPARγ and Runx2.  
Mechanistically, PPARγ directly interacts with Runx2 to prevent Runx2 transcriptional 
activity.(96)  Additionally, PPARγ activation increases β-catenin degradation by the 
50 
 
 
proteasome, removing β-catenin’s support of osteogenesis and β-catenin’s Wnt-mediated 
inhibition of PPARγ expression.(97,100)  However, it is becoming clear that activation of 
adipogenesis and suppression of osteogenesis are distinct and separable activities of 
PPARγ,(210) with ligands having selective abilities to impact adipogenesis and 
osteogenesis.(73,211,212)  Therefore, it is important to examine environmental PPARγ 
ligands for their effects on both adipogenesis and osteogenesis. 
 Interestingly, the effect of TBT and TPhT on osteogenesis was markedly more 
severe compared to the other ligands.  The results with TBT are in line with studies 
demonstrating that TBT suppressed alkaline phosphatase activity in rat calvarial 
osteoblasts and reduced mineralization in adipose-derived stromal cells.(60,226) The 
organotins were disproportionately efficacious in suppressing bone than inducing 
adipogenesis.  One potential explanation for this dichotomy is that the organotins more 
readily activate the anti-osteogenic functions of PPARγ than its pro-adipogenic functions.  
These PPARγ functions were recently shown to be separable, and the anti-osteogenic 
effects of PPARγ were shown to be dependent upon Wnt10b.(209)  However, while 
treatment with TBT, TPhT and MEHP appeared to suppress expression of Wnt10b, the 
effect was not statistically significant. These data suggest that unique modulation of a 
Wnt10b-mediated pathway by organotins does not appear to explain their selective effect 
on MSC differentiation. 
 The toxicants studied here join a growing list of environmental contaminants that 
compromise bone quality, an effect not exclusive to PPARγ ligands.  Processes mediated 
by aryl hydrocarbon receptor ligands (e.g. 2,3,7,8-tetrachlorodibenzo-p-dioxin, benzo-a-
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pyrene) contribute to increased bone resorption in vivo(202) and impair MSC 
differentiation in vitro.(204)  Additionally, co-exposure to dioxin and TBT appears to 
exacerbate the effects of exposure to each toxicant individually.(228) Heavy metals such as 
lead and arsenic are toxic to the skeleton of rats, causing decreased bone density, 
mineralization and strength.(174,184) It is largely unknown how complex exposures to 
multiple bone-suppressive toxicants may act cooperatively to impair bone quality. 
 Our results show that environmental PPARγ ligands are efficacious promoters of 
lipid accumulation and suppress osteogenesis in a mouse bone marrow-derived MSC 
model.  While the efficacies varied by chemical and endpoint, it is important to note that 
effects were observed at environmentally-relevant concentrations.  Additional concern 
should be directed towards identifying possible interactions and how multiple, 
simultaneous exposures could additively suppress bone formation in MSCs.  While this 
study tested exposures on an individual toxicant basis, environmental exposures to these 
chemicals are likely to occur simultaneously.  Further experiments should aim to assess 
chemical mixtures of ubiquitous and persistent compounds in order to more accurately 
characterize toxicant-induced bone loss. 
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Tables 
Table 2.1.  EC50, maximal activation values, and Hill coefficients for mPPARγ activation by selected toxicants.  Values 
are fit estimates from 4-parameter Hill plot using Prism (GraphPad software, Inc. La Jolla, CA).  Maximal fold change in 
PPARγ activation (Max) represents the difference between estimated curve maximum and minimum for each individual 
chemical.  n = 4–6 separate transfection experiments. 
 
 mPPARγ1 mPPARγ2 
Ligand EC50 (M) Max Hill coeff. EC50 (M) Max Hill coeff. 
Rosiglitazone 3.4 x 10-8 3.9 0.9 3.0 x 10-8 4.1 1.0 
TBT 1.0 x 10-8 3.6 1.9 1.7 x 10-8 5.0 1.0 
TPhT 4.0 x 10-8 4.8 1.2 5.0 x 10-8 5.5 1.1 
MEHP 2.4 x 10-5 2.4 1.3 2.9 x 10-5 2.7 1.2 
METBP 1.8 x 10-4 1.3 2.1 2.0 x 10-4 1.4 3.3 
TBBPA 3.9 x 10-6 1.5 1.2 7.8 x 10-6 2.0 0.8 
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Figures 
FIGURE 2.1.  Environmental toxicants activate PPARγ1 and PPARγ2 with differing 
potencies and efficacies.   
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Figure 2.1.  Environmental toxicants activate PPARγ1 and PPARγ2 with differing 
potencies and efficacies.  Cos-7 cells transfected with mouse PPARγ1 or PPARγ2 and a 
PPRE-luciferase reporter plasmid were treated with the indicated compounds.  
Luminescence normalized to GFP fluorescence was divided by the normalized 
luminescence of untreated cultures to calculate fold change from untreated.  n = 4–6 
independent transfections.   
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FIGURE 2.2.  Known modulators of adipogenesis increase lipid accumulation and 
expression of adipogenic genes in mouse BM-MSCs. 
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Figure 2.2.  Known modulators of adipogenesis increase lipid accumulation and 
expression of adipogenic genes in mouse BM-MSCs.  Primary bone marrow cultures 
were established from male C57BL/6J mice and treated with vehicle (Vh, DMSO), 
rosiglitazone (Rosi, 100 nM) or TBT (100 nM) in the presence of osteoinductive media 
for 7 (gene expression) or 11 days (lipid accumulation).  (A) Lipid accumulation was 
quantified by Nile Red staining. (B-D) mRNA expression was quantified by RT-qPCR. 
Data are presented as means ± SE (n = 4–8 independent bone marrow preparations).  *p < 
0.05, **p < 0.01 compared to Vh-treated cultures (ANOVA, Dunnett’s). Vehicle-treated 
cells showed increases in expression of adipocyte-related genes relative to 
undifferentiated cells (1.9-fold for PPARγ, 7.7-fold for Fabp4, and 144.4-fold for Plin1).   
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FIGURE 2.3.  Structurally distinct environmental PPARγ ligands induce lipid 
accumulation and adipogenic gene expression in mouse BM-MSCs.   
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Figure 2.3.  Structurally distinct environmental PPARγ ligands induce lipid 
accumulation and adipogenic gene expression in mouse BM-MSCs.  Primary bone 
marrow cultures were established from male C57BL/6J mice and treated with Vh 
(DMSO), TPhT (10–80 nM; A), MEHP (10–20 μM; B), METBP (10–20 μM; C) or 
TBBPA (10–20 μM; D) in the presence of osteoinductive media for 7 (gene expression) 
or 11 days (lipid accumulation).  Lipid accumulation was quantified by Nile Red staining.  
mRNA expression was quantified by RT-qPCR.  Data are presented as means ± SE (n = 
4–8 independent bone marrow preparations).  *p < 0.05, **p < 0.01 compared to Vh-
treated cultures (ANOVA, Dunnett’s). 
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FIGURE 2.4.  Environmental PPARγ ligands induce perilipin protein expression in 
mouse BM–MSCs.   
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Figure 2.4.  Environmental PPARγ ligands induce perilipin protein expression in 
mouse BM–MSCs.  Primary bone marrow cultures were established from male 
C57BL/6J mice and treated with Vh (DMSO), rosiglitazone (Rosi, 100 nM), TBT (100 
nM), TPhT (50 nM), MEHP, TBBPA, or METBP (20 μM) in the presence of 
osteoinductive media.  Cells were harvested after 7 days. Perilipin and β-actin expression 
were determined in whole cell lysates by immunoblot.  Image is representative of 4 
separate experiments.  
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FIGURE 2.5.  Rosiglitazone and TBT suppress osteogenesis in mouse BM-MSCs. 
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Figure 2.5.  Rosiglitazone and TBT suppress osteogenesis in mouse BM-MSCs.  
Primary bone marrow cultures were established from male C57BL/6J mice and treated 
with vehicle (Vh, DMSO), rosiglitazone (Rosi, 100 nM) or TBT (100 nM) in the 
presence of osteoinductive media for 7 (gene expression) or 11 days (osteogenesis 
assays).  (A) Osteogenesis was assessed via alkaline phosphatase activity, alizarin 
staining and bone nodule counting.  (B) mRNA expression was quantified by RT-qPCR. 
Data are presented as means ± SE (n = 5–8 independent bone marrow preparations).  *p < 
0.05, **p < 0.01 compared to Vh-treated cultures (ANOVA, Dunnett’s). 
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FIGURE 2.6.  Structurally distinct environmental PPARγ ligands suppress 
osteogenesis in mouse BM-MSCs. 
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Figure 2.6.  Structurally distinct environmental PPARγ ligands suppress 
osteogenesis in mouse BM-MSCs.  Primary bone marrow cultures were established 
from male C57BL/6J mice and treated with Vh (DMSO), TPhT (10–80 nM; A), MEHP 
(10–20 μM; B), METBP (10–20 μM; C), or TBBPA (10–20 μM; D), in the presence of 
osteoinductive media for 11 days.  Osteogenesis was assessed by alkaline phosphatase 
activity, alizarin staining and bone nodule counting.  Data are presented as means ± SE (n 
= 5–8 independent bone marrow preparations).  *p < 0.05, **p < 0.01 compared to Vh-
treated cultures (ANOVA, Dunnett’s). 
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FIGURE 2.7.  Structurally distinct environmental PPARγ ligands suppress 
osteogenic gene expression in mouse BM-MSCs. 
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Figure 2.7.  Structurally distinct environmental PPARγ ligands suppress osteogenic 
gene expression in mouse BM-MSCs.  Primary bone marrow cultures were established 
from male C57BL/6J mice and treated with Vh (DMSO), TPhT (10–80 nM; A), MEHP 
(10–20 μM; B), METBP (10–20 μM; C), TBBPA (10–20 μM; D) in the presence of 
osteoinductive media for 7 days.  mRNA expression was quantified by RT-qPCR.  Data 
are presented as means ± SD (n = 4–7 independent bone marrow preparations).  *p < 
0.05, **p < 0.01 compared to Vh-treated cultures (ANOVA, Dunnett’s). 
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FIGURE 2.8.  Adipogenesis is inversely correlated with osteogenesis in PPARγ-
ligand treated mouse BM-MSCs.   
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Figure 2.8.  Adipogenesis is inversely correlated with osteogenesis in PPARγ-ligand 
treated mouse BM-MSCs.  Data points are representative of mean endpoint values for 
individual treatments and concentrations reported in Figs 2.2, 2.3, 2.5, 2.6, 2.7.  (A) Fold 
change in alkaline phosphatase activity vs. lipid accumulation (Nile Red fluorescence) 
(All data Pearson’s r = -0.51).  (B) Bone nodule number vs. lipid accumulation (All data 
Pearson’s r = -0.01).  (C) Osx mRNA expression vs. Fabp4 mRNA expression (All data 
Pearson’s r = -0.57).  ■ – Vh (DMSO); □ – Rosiglitazone (100 nM); ● – METBP; ○ – 
MEHP; Δ – TBBPA; x – TBT or TPhT.  Linear fit excludes organotin data points (x).  r = 
Pearson’s correlation coefficient (excluding organotins), number of pairs = 8.  
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FIGURE 2.9.  Differential suppression of osteogenic Wnt10b mRNA does not explain 
efficacious effect of organotins on osteogenesis.   
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Figure 2.9.  Differential suppression of osteogenic Wnt10b mRNA does not explain 
efficacious effect of organotins on osteogenesis.  Primary bone marrow cultures were 
established from male C57BL/6J mice and treated with Vh (DMSO), rosiglitazone (100 
nM), TBT (100 nM), TPhT (10–80 nM), MEHP (10–20 μM) in the presence of 
osteoinductive media for 7 days.  mRNA expression was quantified by RT-qPCR. Data 
are presented as means ± SE (n = 4–10 independent bone marrow preparations).  *p < 
0.05, **p < 0.01 compared to Vh-treated cultures (ANOVA, Dunnett’s). 
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Supplemental material 
Supplementary Table S2.1.  Primers used for mRNA expression analysis. 
Gene 
Symbol 
NCBI Reference 
Sequence 
Qiagen 
Catalog # 
   
Dmp1 NM_016779 QT01078210 
Fabp4 NM_024406 QT00091532 
Plin1 NM_001113471 
NM_175640 
QT00150360 
Pparg 1/2 NM_001127330, 
NM_011146 
QT00100296 
Rn18s  X00686, 
NR_003278 
QT01036875 
Runx2 NM_009820 QT00102193 
Osx NM_130458 QT00293181 
Wnt10b NM_011718 QT00113211 
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Supplementary Figure S2.1 – Toxicity of TBT, TPhT, METBP, TBBPA and MEHP. Primary bone marrow cultures were 
established from male C57BL/6J mice and treated with vehicle (Vh, DMSO), TBT (100 nM), TPhT (10–80 nM), MEHP (10–
20 μM), METBP (10–20 μM), or TBBPA (10–20 μM) in the presence of MSC medium 10 days. Cellularity was assessed by 
analyzing MTT labeling.  Data are presented as means ± SE (n=4–8). No statistically significant differences were observed in 
experimental samples (ANOVA). 
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Abstract  
The balance of bone formation and resorption is controlled by a precise coupling between 
osteoblasts and osteoclasts, respectively. Nuclear receptors transcriptionally modify 
differentiation and function of both cell types, thus activation of nuclear receptors by 
exogenous compounds can perturb overall bone homeostasis. The retinoid-X receptor 
alpha (RXRα), peroxisome proliferator activated receptor gamma (PPARγ) and the liver-
x receptors (LXRs) all have been shown to influence bone homeostasis. Tributyltin 
(TBT) is an environmental contaminant that is a dual RXRα and PPARγ agonist that 
induces RXR, PPARγ and LXR-mediated gene transcription and suppresses osteoblast 
differentiation in vitro. In these studies, 12-week old female wild-type C57Bl/6J mice 
were exposed to 10 mg/kg TBT for 10 weeks via oral gavage. As expected, the femurs of 
TBT-treated mice had a smaller cross-sectional area and thinner cortex. Surprisingly, 
TBT induced significant increases in trabecular thickness, number, and fractional bone 
volume, along with a decrease in trabecular spacing. Histological analyses showed that 
the observed increase in bone was not due to a lack of osteoclasts in the trabecular space. 
Analyses of whole bone RNA indicated that TBT treatment did not change the 
Rankl:Opg ratio, suggesting that osteoblast stimulation of osteoclasts was not suppressed. 
However, expression of cardiotrophin-1 (Ct1), an osteoblastogenic Il-6 family cytokine 
secreted by osteoclasts, was increased. In TBT-exposed primary bone marrow cultures 
stimulated to differentiate into osteoclasts, TBT did not inhibit the number of osteoclasts 
that differentiated, despite the fact that expression of osteoclast markers Nfatc1, Acp5 and 
Ctsk decreased. However, Ct1 expression remained elevated in TBT-treated cultures. 
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Additionally, TBT induced expression of LXR- and RXR-dependent genes in whole bone 
and in vitro osteoclast cultures. These results suggest that TBT has a distinct effect on 
cortical and trabecular bone, likely resulting from independent effects on osteoblast and 
osteoclast differentiation that are mediated through multiple nuclear receptors.   
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Introduction 
Bone remodeling is a coordinated sequence of bone resorption followed by bone 
formation, orchestrated by the activity of osteoclasts and osteoblasts, respectively. 
Maintenance of bone and mineral homeostasis requires tight regulation of this coupled 
process. Where an imbalance favors the activity of osteoclasts, resorption prevails over 
mineral deposition and overall bone quality decreases, potentially leading to pathologic 
states of osteopenia and osteoporosis. Conversely, inherited mutations causing 
impairments of osteoclast differentiation or function can result in osteopetrotic states of 
overly dense and brittle bone. 
Communication between the two cell types allows for local control of the 
resorption-formation coupling. For example, osteoblasts produce macrophage colony 
stimulating factor (M-CSF) and receptor activator of nuclear factor kappa B ligand 
(RANKL).(120,125) Upon interacting with hematopoietic precursor cells, these two factors 
are sufficient to promote differentiation of mature osteoclasts via downstream activation 
of the transcription factor Nfatc1.(110,123,229) The RANKL signal is suppressed by the 
soluble osteoprotegerin (OPG), also expressed by osteoblasts.(230) Osteoclasts reciprocally 
produce and secrete cytokines (e.g. cardiotrophin-1)(135)  that support the maturation of 
osteoblasts to regenerate the collagenous mineral tissue removed during resorption, as 
well as provide inhibitory signals (e.g. Semaphorin 4D)(137) to suppress osteoblast activity 
during the resorption phase. Impairment of the function of one cell type may therefore 
have indirect effects on the differentiation or function of the other.  
Multiple aspects of osteoblast and osteoclast differentiation and function are 
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influenced by nuclear receptors, which respond to endogenous and exogenous ligands. 
The peroxisome proliferator activated receptor γ (PPARγ) and liver-x receptors α and β 
(LXRα and LXRβ) are members of the nuclear receptor superfamily that form permissive 
heterodimers with the retinoid-x receptor alpha (RXRα), which can also 
homodimerize.(8,26,231) All four receptor types are expressed in osteoblasts and 
osteoclasts.(72)  
Transactivation of PPARγ in bone marrow mesenchymal osteoblast precursors by 
synthetic agonists, such as rosiglitazone, induces differentiation along the adipocyte 
lineage and suppresses osteoblast differentiation.(15,16) In osteoclasts, PPARγ is essential 
for differentiation via support of RANKL signaling.(232,233) In vivo exposure to 
rosiglitazone results in decreased bone quality and increased fat content in the marrow 
space.(74–76)  
LXR agonism in vivo has been shown to attenuate osteoclast-mediated bone loss 
in ovariectomized and inflammatory-induced bone loss mouse models.(234,235) However, 
long-term treatment in vivo with a synthetic LXR-specific agonist appears to have no net 
positive effect on bone mineral content in an intact mouse model.(236)  
RXR activation plays maturation-dependent roles in osteoclasts. In osteoclast 
precursors, RXR homodimer activity maintains a high level of Mafb expression, which is 
necessary for a proper proliferative response to M-CSF.(13) In differentiating osteoclasts, 
RXRα:LXR activation suppresses osteoclast function and differentiation by interfering 
with RANKL signaling.(13,237)  
The environmental contaminant tributyltin (TBT) is a dual PPARγ and RXRα 
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agonist shown to activate RXR homodimers, as well as PPARγ:RXRα(58,63,81) and 
LXR:RXRα(81,238) heterodimers and is a recognized bone toxicant. In utero exposure to 
TBT prevents ossification in mouse fetuses and predisposes stromal cells to favor 
adipogenesis by epigenetic modifications at PPARγ target promoters.(60,226) In vitro, TBT 
suppresses the osteoblastogenic transcription factors Runx2 and osterix while activating 
PPARγ:RXRα. This promotes commitment of bone marrow mesenchymal stromal cells 
(BM-MSCs) towards an adipocyte lineage at the expense of bone mineralization in a 
manner similar to rosiglitazone.(60,80–82,239) In contrast to rosiglitazone, TBT was shown to 
suppress osteoclast differentiation and resorptive capacity at nanomolar concentrations in 
Raw264.7 cells;(240) however, these cells do not express significant levels of PPARγ, 
RXRs or LXRs.(13) It has not been established as to which of these effects predominates 
to determine a bone phenotype in adult mice exposed to TBT. 
The studies herein were designed to determine the overall effect of in vivo TBT 
exposure on long bones of skeletally mature, adult, female C57Bl/6 mice, and to 
characterize the role of TBT, as an activator of multiple nuclear receptor pathways, in the 
balance of osteoblast and osteoclast function. 
 
Materials and Methods 
Rosiglitazone was from Cayman Chemical (Ann Arbor, MI). DMSO was from 
American Bioanalytical (Natick, MA). LG100268, T0901317, p-nitrophenyl phosphate 
(pNPP) reagent, TBT chloride, Gil’s Hematoxilin and sodium tartrate were from Sigma-
Aldrich (St. Louis, MO). All other reagents were from Thermo Fisher Scientific 
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(Suwanee, GA) unless noted. 
 
In vivo studies 
All animal studies were approved by the Institutional Animal Care and Use 
Committee at Boston University. Female C57BL/6J mice (12 weeks of age) (Jackson 
Laboratories, Bar Harbor, ME) were gavaged 3x per week for 10 weeks with vehicle 
(sesame oil, 10 μl/g), or TBT (10 mg/kg dissolved in sesame oil). Mice were euthanized 
four days after the last dosing. At euthanasia, the right femur was collected for microCT 
and histological analyses; humeri were collected for RNA analyses. Serum was collected 
at euthanasia for analysis of bone turnover markers.  
 
Micro-Computed Tomography (micro-CT) 
Sample analyses were performed according to guidelines outlined in Bouxsein et 
al. (2010).(241) Samples were scanned at a resolution of 6 m/voxel using a Scanco micro-
CT 40 system (Scanco Medical; Basserdorf, Switzerland). Trabecular bone was analyzed 
in the distal femur, with the region of interest beginning 0.03 mm proximal to the growth 
plate and extending 0.9 mm proximally. The trabecular compartment was manually 
segmented from the cortical shell. Cortical bone was analyzed from 12 m/voxel scans of 
a 0.6 mm region extending proximally from the mid-diaphysis. Treatment-specific 
thresholding was used with thresholds determined by an iterative method (Scanco 
Medical). Tissue mineral density was calculated with the aid of a standard curve obtained 
from a scan of a hydroxyapatite phantom consisting of five different mineral densities.  
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Histology and Immunohistochemistry 
Following micro-CT scans, femurs were decalcified in 14% w/v EDTA at 4°C 
and embedded in paraffin. 5m slices were stained with hematoxylin and eosin or with 
tartrate resistant acid phosphatase, as previously described.(242) Micrographs were 
visualized on an Olympus BX51 light microscope (Olympus America Inc.; Center 
Valley, PA). Osteoclast surface, osteoclast number, and adipocyte number were 
determined manually within a 1.5 mm selection proximal to the growth plate.   
 
Primary osteoblast cell culture 
Bone marrow was isolated from 9-week-old male and female, C57BL/6J mice 
(Jackson Laboratories). Bone marrow was flushed from the femur, tibia, and humerus, 
strained through a 70 μm cell strainer, diluted in MSC media (α-MEM +10% FBS, 100 
U/mL penicillin, 100 μg/mL streptomycin, 0.25 μg/mL amphotericin B). Cells were 
seeded at 12 × 106 per well in a 6-well plate in 2 ml media. At 7 days, the medium was 
changed to include ascorbate (12.5 μg/mL), β-glycerol phosphate (8 μM), dexamethasone 
(10 nM; Sigma), and insulin (500ng/mL; Sigma), and the cultures were dosed with Vh 
(DMSO, 0.1% final concentration) or TBT (10, 50nM). Naïve cells were maintained in 
MSC medium, received no treatments, and were harvested at day 7 in culture. Following 
initiation of differentiation, cells were cultured for 7 days (mRNA expression) or 12 days 
(bone phenotype).  During these periods, medium was changed and the cultures were re-
dosed 2 times for mRNA expression or 4 times for phenotype analysis.   
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Primary osteoclast culture  
Bone marrow was isolated from 12-week-old female, C57BL/6J mice (Jackson 
Laboratories). Following overnight incubation in MSC media with 25 ng/ml recombinant 
human M-CSF (BioLegend, San Diego, CA), suspended cells from whole bone marrow 
were collected and seeded at 3 x 106 per well in a 6-well plate with 2 ml media (gene 
expression) or 2.5 x 104 per well in a 24-well plate with 1 ml media (TRAP+ MuNC 
counts; resorption assay) with 50 ng/ml M-CSF. On day 1, recombinant murine RANKL 
(BioLegend) was added at 50 ng/ml. On days 2 and 4, media and additives were replaced 
and treatments (Vh, TBT (20, 50, 80 nM), rosiglitazone (100 nM), LG100268 (100 nM), 
or T0901317 (100 nM)) were added. Cells were harvested on day 6.   
 
Tartrate-resistant acid phosphatase (TRAP) staining 
Osteoclast cultures were rinsed with PBS and fixed in 4% paraformaldehyde 
(Sigma). Membranes were permeabilized with ethanol/acetone (1:1) and stained with 
sodium tartrate (50 mM). Cultures were counterstained with Gil’s Hematoxilin solution. 
Multi-nucleated (3 or more nuclei), TRAP-positive cells were counted manually. 
 
Mineral resorption assay 
Osteoclast precursors were seeded at 2.5 x 104 per well in a 24-well Corning 
OsteoAssay plate (Corning, Corning NY) and treated, as above. On day 6, cells were 
removed with 10% bleach. The mineral surface was rinsed with distilled water and dried 
for 3 hours at room temperature. Surfaces were visualized at 10x magnification using an 
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EVOS XL Imaging System (Thermo Fisher/Life Technologies; Carlsbad, CA). 4–5 fields 
of view per well were manually thresholded and resorption pit number, size, and area 
were determined using Image J (NIH; http://imagej.net). Objects smaller than 1,100 µm2 
in area were excluded.  
 
Reverse transcriptase-qPCR 
Cell culture: Total RNA was extracted and genomic DNA was removed using the 
RNeasy Plus Mini Kit (Qiagen, Valencia, CA). cDNA was prepared from total RNA 
using the GoScript™ Reverse Transcription System (Promega), with a 1:1 mixture of 
random and Oligo (dT)15 primers. All qPCR reactions were performed using the GoTaq® 
qPCR Master Mix System (Promega). Validated primers were purchased from Qiagen or 
synthesized by Integrated DNA Technologies (Coralville, IA) (see Table S1). qPCR 
reactions were performed using a 7300 Fast Real-Time PCR System (Applied 
Biosystems, Carlsbad, CA): Hot-Start activation at 95°C for 10 min, 40 cycles of 
denaturation (95°C for 15 sec) and annealing/extension (55°C or 60°C for 60 sec). 
Relative gene expression was determined using the Pfaffl method to account for 
differential primer efficiencies.(223) The average Cq value for 18s ribosomal RNA (Rn18s) 
and beta-2-microglobulin (B2m) was used for normalization. The Cq value for naïve, 
undifferentiated cultures was used as the reference point, and the data are reported as 
“Fold Difference.”   
 Whole bone: Total RNA was extracted and genomic DNA removed by double 
TRIzol® extractions (Life Technologies, Grand Island, NY). RNA integrity was 
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confirmed by gel electrophoresis. cDNA preparation and RT-qPCR were performed as 
above. The Cq value for naïve, 22 week old, male, C57BL/6J-derived humerus samples 
(n = 5) was used as a reference point, and expression levels were normalized to the 
sample-specific Cq average of Rn18s, B2m and hypoxanthine-guanine 
phosphoribosyltransferase (Hprt), and the data are reported as “Fold Difference.” 
 
Statistical analyses 
Statistical analyses were performed with Prism 6 (GraphPad Software Inc., La 
Jolla, CA).  Data are presented as means  standard error (SE).  In vitro gene expression 
data were log transformed prior to analysis.  One-way or two-way ANOVAs with the 
Dunnett’s or Sidak’s post hoc test and unpaired t-tests were performed where noted. 
Because of skewed distribution, non-parametric Mann-Whitney test was used for whole 
bone RNA analyses. All analyses were performed at α = 0.05.   
 
Results 
Effect of TBT on osteogenic differentiation in vitro 
We and others have previously documented TBT’s capability to suppress the in 
vitro differentiation of mesenchymal stromal cells.(60,80,226,239) Initial studies herein were 
designed to compare TBT’s in vitro efficacy and potency between male and female 
C57Bl/6J mice. Primary bone marrow mesenchymal stromal cells (BM-MSC) were 
harvested from 9-week old female and male C57Bl/6J mice and cultured in the presence 
of l-ascorbate, β-glycerol phosphate, insulin and dexamethasone, and dosed with either 
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Vh (DMSO) or TBT (10 nM, 50 nM). Total RNA was harvested after 7 days to assess 
relative gene expression, and analyses of bone nodule formation were conducted after 10 
days. 
As expected, TBT suppressed the expression of pro-osteogenic genes at 
nanomolar concentrations in both male- and female-derived cultures (Figure 3.1a). Runx2 
is the master regulator of osteogenesis and controls the expression of osterix (Osx), which 
also is an essential osteogenic transcription factor.(99) Dentin matrix phosphoprotein 1 
(Dmp1) is expressed by mineralizing osteocytes and regulates biomineralization and 
mineral metabolism.(105) Levels of Runx2 expression in Vh-treated cultures were 
comparable between sexes, although TBT only significantly decreased its expression in 
female-derived cultures (Figure 3.1a, left panel). Osx was expressed at a higher level in 
female-derived cultures. TBT reduced Osx expression in both male- and female-derived 
cultures, however TBT more potently and efficaciously suppressed expression in female-
derived cultures (Figure 3.1a, center panel). Levels of Dmp1 were lower overall in 
female-derived cultures, and TBT significantly suppressed Dmp1 expression in both 
male- and female-derived cultures. It should be noted that the relative expression level of 
Dmp1 in cultures treated with 50 nM TBT was 30x lower in female-derived cultures 
compared to male-derived cultures (Fold Difference: 16.4 ± 6.2 vs. 558 ± 195, 
respectively) (Figure 3.1a, right panel).  
The dimorphic response was more pronounced in the bone mineralization assays. 
TBT significantly inhibited alkaline phosphatase activity at both 10 and 50 nM in female-
derived cultures, but only at 50 nM in male cultures (Figure 3.1b). This pattern also was 
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evident in the number of bone nodules and mineral deposition (Figure 3.1b), with each 
being more severely inhibited in female-derived cultures than in male-derived cultures. 
From these data, we conclude that, in vitro, TBT disproportionately suppresses the 
differentiation and function of BM-MSCs in female-derived cultures.  
 
Effect of TBT on bone homeostasis in vivo 
Because we observed a pronounced sensitivity to TBT in female-derived primary 
bone marrow cultures, we hypothesized that in vivo exposure to TBT would produce an 
overall deficit of bone tissue in the long bones of female C57Bl/6J mice. To test this 
hypothesis, 12-week old female, non-ovariectomized mice were treated 3x/week for 10 
weeks with either vehicle (sesame oil) or TBT (10 mg/kg bw) by oral gavage. TBT 
treatment induced slightly larger increases in body weight relative to initial weight, but 
thymus weight relative to body weight (a measure of systemic TBT toxicity) at 
euthanasia was not affected (Figure S3.1).  
At the end of the treatment period, micro-CT was used to determine TBT’s impact 
on long bone microarchitecture. A femur was harvested from each mouse (n = 12 control, 
11 TBT), and the cortical and trabecular compartments were analyzed at the diaphysis 
and metaphysis, respectively (Figure 3.2). Overall, a slight decrease in cortical cross-
sectional area was evident from visual inspection of the 3D reconstructions (Figure 3.2a). 
As expected from the in vitro results, cortical thickness (Ct.Th) and total bone area 
(Ct.Ar) at the diaphysis were significantly decreased by TBT treatment (Figure 3.2b, top 
left and top center). In TBT-treated mice, medullary area (Ma.Ar) decreased in parallel 
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with total area (Tt.Ar), resulting in a ratio of bone area to total area that was 
indistinguishable from Vh-treated mice (Ct.Ar/Tt.Ar) (Figure 3.2b). At the mid-
diaphysis, total mineral density, measured as mg of hydroxyapatite per mm2, was not 
affected by treatment (Figure 3.2b, bottom right).  
In the trabecular compartment, TBT treatment unexpectedly was associated with a 
robust increase in trabecular mineralization that was clearly discernable in the 
reconstructions (Figure 3.2c). The fraction of total area occupied by bone in the 
medullary space (BV/TV) was significantly increased in the TBT-treated mice (Figure 
3.2d, top left), and the tissue mineral density was increased (Figure 3.2d, top center). The 
connective density (Conn.D) and number of trabeculae (Tb.N) increased with TBT 
treatment (Figure 3.2d, top right and bottom left, respectively) as trabecular spacing 
(Tb.Sp) decreased (Figure 3.2d, bottom center). The average trabecular thickness was not 
affected (Tb.Th) (Figure 3.2d, bottom right).  
Histological analyses were carried out to corroborate the structural data (Figure 
3.3). An increased density of trabeculae was evident in femur sections of TBT-treated 
mice (Figure 3.3a). Adipocyte number was highly variable in the TBT-treated bone 
sections, and tended to be higher than in Vh (Figure 3.3b). Expression of the adipocyte 
marker perilipin 1 (Plin1) RNA in whole bone was higher with TBT, although with 
borderline significant (p = 0.063) (Figure 3.3c). With regard to osteoblast differentiation 
and function, 10 mg/kg TBT treatment was associated with a slight but non-significant 
increase in Runx2 and no change in Osx (Figure 3.3d). In accordance with the structural 
data, TBT significantly increased the expression of Dmp1 (Figure 3.3d). There was no 
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change in the expression of Sost, an osteocyte-derived bone formation inhibitor (Figure 
3.3d). 
Increases in bone density can result from an increase in osteoblast activity, a 
decrease in osteoclast number, and/or a decrease in osteoclast resorptive function.(243) 
Therefore, we investigated the potential contribution of osteoclasts to the observed 
phenotype. Histological sections of the distal femur were tartrate-resistant acid 
phosphatase (TRAP) stained to visualize and quantify the osteoclast population (Figure 
3.4a). TBT treatment did not cause a significant decrease in osteoclast coverage of 
trabecular surface (Figure 3.4b). Additionally, there was no change in serum TRAP levels 
between Vh- and TBT-treated mice (Figure 3.4c), suggesting that osteoclast number had 
not substantially decreased with TBT treatment.   
 Transcript levels of Nfatc1, Acp5, and Ctsk were measured to assess TBT’s effect 
on osteoclast differentiation and resorptive capacity. Nfatc1 is a transcription factor 
required for osteoclast differentiation and function.(124) Trap5b, the protein product of 
Acp5, is a lysosomal acid phosphatase involved in processing of non-collagenous proteins 
(e.g. osteopontin) in osteoclasts during bone resorption.(244) Cathepsin K is a lysosomal 
cysteine proteinase involved in bone resorption.(245) TBT treatment was associated with 
significant decreases in Nfatc1 and Acp5, along with a slight but non-significant decrease 
in Ctsk expression (Figure 3.4d). Osteoblast stimulation of osteoclast differentiation was 
assessed by measuring relative levels of Rankl and Opg expression. Overall, TBT 
increased mRNA expression levels of both proteins (data not shown), but the ratio of 
Rankl:Opg was not altered from Vh-treated samples (Figure 3.4e). However, TBT was 
88 
 
 
8
8
 
associated with a significant increase in the expression of the pro-osteogenic cytokine 
cardiotrophin 1 (Ct1)(135) (Figure 3.4e), suggesting a mechanism of increased osteoblast 
stimulation by osteoclasts.  
Together, these differences suggest diminished periosteal modeling and 
potentially diminished endosteal resorption along the diaphysis associated with TBT 
treatment. Measures of whole bone RNA transcripts suggest that TBT treatment perturbs 
the balance between osteoblasts and osteoclasts in the trabecular compartment to favor 
osteoblast activity and effect mineralization. 
 
Effects of TBT on osteoclast differentiation in vitro 
To determine whether TBT treatment resulted in dose-dependent transcription 
and/or functional changes in osteoclasts specifically, primary bone marrow macrophages 
from C57Bl/6J females were cultured in the presence of M-CSF and RANKL to induce 
differentiation into mature osteoclasts. After 24 hours of RANKL-induced differentiation, 
cells were treated with either Vh (DMSO) or TBT (20, 50, or 80 nM), and total RNA was 
harvested to assess relative gene expression after 6 days. Consistent with whole bone 
mRNA expression (Figure 3.4d), expression of both Nfatc1 and Acp5 were significantly 
decreased by TBT relative to Vh-treated cultures (Figure 3.5a). Expression Ctsk was also 
significantly decreased by all TBT concentrations (Figure 3.5a). However, the expression 
of Ct1 did not decline and even showed a dose-dependent trend toward increasing with 
TBT concentration (Figure 3.5b). Conversely, TBT significantly suppressed expression 
of the anti-osteogenic semaphorin-4D (Sema4D)(137) (Figure 3.5b).  
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Although the in vivo results suggested no significant change in osteoclast number 
with TBT treatment, the in vitro gene expression analysis suggested a suppression of 
osteoclast differentiation. We therefore examined osteoclast number in vitro by staining 
and quantifying TRAP-positive, multinucleated cells in culture after they were induced to 
differentiate by recombinant RANKL and M-CSF in the presence of either Vh or TBT 
(Figure 3.5c). After 6 days in culture, TBT treatment resulted in a slight, but non-
significant dose-dependent increase in the number of TRAP-positive, multinucleated cells 
(Figure 3.5d). Cell viability, as assessed by MTT activity, was not affected by TBT at 20 
nM or 50 nM, though 80 nM showed a small but significant decrease; cell death (release 
of lactate dehydrogenase) was not altered by TBT (Figure S3.2).  
To assess the relative resorptive function of TBT-treated osteoclasts in vitro, 
osteoclasts were differentiated on a synthetic inorganic surface under the same conditions 
as the TRAP-positive cell count assay. After 6 days, resorption pits were counted and 
sized. All three doses of TBT increased the average number of resorption pits, resulting 
in a greater percentage of the total resorbed surface (Figure 3.5e). The average size of the 
resorption pits did not differ from vehicle control (Figure 3.5e). Representative images 
used for quantification are presented in Figure 3.5f.  
We concluded that TBT exposure does not attenuate the population of osteoclasts 
in vitro or in vivo. The gene expression data suggest that expression of the differentiation 
program is impacted by TBT, but without a significant change in osteoclast cell number 
or resorptive capacity. Rather, the data suggest that TBT modifies the type of osteoclast 
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that differentiates, altering expression of genes related to osteoclast-osteoblast 
communication to favor osteoblastogenesis.  
 
Activation of LXR-dependent pathways by TBT 
Recent literature has highlighted the role of RXRs and LXRs in the 
osteoclast.(13,234,235,237)  Because TBT is a known activator of RXRα(63), and based on 
previous results demonstrating TBT activation of RXR and LXR-dependent genes in 
bone marrow stromal cells (Figure S3.3)(81), we hypothesized that TBT would activate 
RXR and/or LXR-dependent pathways in vivo and in in vitro osteoclast cultures.    
In the whole bone RNA, TBT exposure did not impact the expression of Lxra or 
Lxrb (data not shown). TBT exposure was associated with a significant, 2-fold increase in 
the expression of Abca1, an LXRβ gene target and cholesterol transporter, whereas 
Srebp1c, an LXRα target gene and lipogenic transcription factor, was not significantly 
upregulated (Figure 3.6a). Mafb, a target of either RXR homodimers or SREBP1c, was 
significantly upregulated in samples from TBT-treated animals (Figure 3.6a).  
In the differentiated osteoclast cultures, TBT induced a dose-dependent increase 
in Abca1 expression (Figure 3.6b). The RXR-specific agonist LG100268 induced a 
significant increase in Abca1 expression, implying activation of the RXRα:LXRβ 
permissive heterodimer. This pattern was also seen in the expression of Srebp1c (Figure 
3.6b). As expected, the LXR-specific agonist T0901317 efficaciously induced expression 
of both LXR target genes. By comparison, the PPARγ-specific agonist rosiglitazone did 
not induce expression of Abca1 or Srebp1c above the Vh control baseline. Mafb was 
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most efficaciously induced by TBT and LG100268, with no induction by rosiglitazone 
and moderate induction by T0901317 (Figure 3.6b). These results indicate that TBT 
induces activation of multiple nuclear receptors in osteoblasts and osteoclasts.  
 
Discussion 
Nuclear receptors play an important role in determining the differentiation and 
function of both osteoblasts and osteoclasts. Consequently, the balance of bone resorption 
and formation can be perturbed by activation of multiple nuclear receptors. The goal of 
this study was to use tributyltin (TBT), which can directly activate RXRα and PPARγ(63) 
and indirectly activate LXR,(81,238) to examine the in vivo outcomes and in vitro 
mechanisms associated with RXRα dimer-related signaling in bone.  
As a PPARγ agonist, the ability of TBT to induce adipogenesis and suppress 
osteogenesis in differentiating osteoblasts has been characterized.(80,82,226,239) We began 
by re-establishing this effect in primary bone marrow MSCs and found that cells derived 
from female mice are more sensitive to TBT’s ability to suppress osteogenesis than those 
from male mice (Figure 3.1). It is well known that mature female mice have lower 
trabecular density and thinner bones compared to males, and that female-derived 
osteoblasts have lower potential for differentiation.(144,246,247) We have previously shown 
that female-derived BM-MSCs were more sensitive to rosiglitazone-induced suppression 
of osteogenesis.(153) However, this is the first report of TBT displaying a sexually 
dimorphic effect at the transcriptional level.  
Here, we decided to use the increased sensitivity of female mice to TBT to probe 
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in vivo effects of TBT exposure. It has been reported that TBT suppresses ossification in 
fetal mice.(226) The rationale for using skeletally mature mice was that PPARγ-mediated 
bone loss is typically seen among aging individuals on thiazolidinedione therapy for type 
II diabetes,(77,79) and thus mice with fully developed long bones at baseline (12 weeks of 
age) would provide a more relevant model for studying this particular etiology of 
osteoporosis. Furthermore, we wished to isolate the effect of TBT on ongoing modeling 
and remodeling from longitudinal growth. 
The thinner cortex at mid-diaphysis associated with TBT treatment was expected, 
as this phenotype is consistent with the suppression of osteogenesis seen in vitro. Cortical 
bone is built by periosteal bone deposition, and the smaller cortical diameter suggests that 
the thinner cortex resulted from a failure of periosteal bone deposition. Importantly, 
thinner (i.e. smaller cross-sectional area) bones are less structurally sound.(140) Therefore 
this observed phenotype may be associated with increased susceptibility to fracture. On 
the other hand, the medullary space also was smaller in the TBT-treated mice. Osteoclast 
activity on the endosteal surface typically thins cortical bone.  The smaller medullary 
space suggests that osteoclast activity at the endosteal surface is being suppressed by 
treatment with TBT.    
Surprisingly, there was an increase in trabecular bone volume consistent with 
increased osteoblast activity (an increase in trabecular number without an increase in 
average trabecular thickness). This was corroborated by the increased expression of 
Dmp1 (Figure 3.3), which is highly expressed in osteocytes.(105) This increase in bone 
occurred despite the fact that TBT activates PPARγ. In vivo studies with the PPARγ 
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agonist rosiglitazone show clear reduction of trabecular bone in femur of treated animals 
that is accompanied by increased marrow adipocytes.(74–76) Here, TBT-exposed bones 
also showed increased adipogenesis (Figure 3.3a–c). Selective PPARγ activation has 
been shown to increase marrow adiposity without affecting bone density,(211) though TBT 
treatment also induced a clear increase in mineralization. These results suggest either that 
TBT induces an uncoupling of the pro-adipogenic and anti-osteogenic roles of the 
RXRα:PPARγ heterodimer (also suggested by Rahman et al. (2012))(209) or TBT activates 
another pathway altogether.  
Osteoclasts play a dual role in bone, both physically resorbing bone and signaling 
to osteoblasts to initiate bone formation. Nuclear receptors have been shown to be 
influential in regulating osteoclast differentiation. In vivo, osteoclast number can be 
increased by a PPARγ agonist, though this effect is controversial.(232,233,248) LXR agonists 
can protect against ovariectomy-induced bone loss by reducing osteoclast number.(234,235) 
RXR homodimers maintain the response to M-CSF in pre-osteoclasts, but as a 
heterodimer with LXR can suppress RANKL signaling in differentiating osteoclasts.(13) 
The histological counts of osteoclasts and serum TRAP measurements indicated that 
osteoclast number was not substantially altered by TBT in vivo, and TBT also did not 
reduce osteoclast numbers in vitro. Therefore, a reduction in osteoclast number likely 
does not explain the increased mineralization. However, this lack of change in osteoclast 
number is inconsistent with the observed changes in gene expression from whole bone 
(humerus) or osteoclast culture, where TBT suppressed osteoclast differentiation and 
function markers (Figures 3.4 and 3.5, Nfatc1, Trap, Ctsk). The discrepancy between the 
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suppression of Nfatc1 in whole bone RNA, which would predict an overall decrease in 
osteoclast number, and the histological data may in part be explained by assay sensitivity, 
where the magnitude of Nfatc1 suppression is not sufficient to impact the population of 
osteoclasts observed directly in the trabecular compartment. Additionally, in vitro 
osteoclast cultures may be more sensitive to chemical perturbation due to the use of only 
recombinant M-CSF and soluble RANKL rather than osteoblast-facilitated 
differentiation.(122)  
In the in vitro functional assay, TBT increased the number of resorption pits, 
suggesting that the capacity of TBT-exposed osteoclasts to resorb inorganic bone matrix 
was increased. Fuller et al. (2008) have shown that inhibition of Cathepsin K, secreted by 
osteoclasts, prevents the degradation of anabolic signals (e.g. IGF-1) stored in the 
inorganic matrix and increases their activity,(249) and this may provide a mechanism for 
the observation of increased mineralization in cathepsin K-deficient mice.(250) Given the 
suppression of Ctsk in TBT-treated cultures and whole bone RNA, it is possible that 
osteoclasts in TBT-exposed mice have a decreased capacity to degrade osteogenic matrix 
proteins, though not necessarily a diminished capacity to resorb inorganic material. As a 
result, there may be an increase the local concentration of anabolic factors as they are 
released from the matrix and not degraded, contributing to the observed increase in 
trabecular mineralization.  
Notably, expression of the Il-6 family cytokine cardiotrophin-1 (Ct-1) was 
increased by TBT both in vivo and in vitro. Ct-1 is essential for osteoclast function, but 
also acts as a stimulatory signal for osteogenesis.(135) On the other hand, TBT treatment 
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suppressed Sema4d expression in vitro, which inhibits osteoblastogenesis under normal 
conditions(137) (whole bone expression of Sema4d was not significantly different between 
Vh and TBT treated groups (data not shown)). Together, these expression profiles 
suggest a change in the function of osteoclasts at the transcriptional level rather than an 
overall change to the osteoclast population. This finding also supports the role of 
osteoclast-osteoblast communication as a major determinant of TBT induced changes in 
trabecular density, particularly in light of the finding that the Rankl:Opg ratio is not 
decreased with TBT treatment (Figure 3.4), implying no effect on osteoblast-mediated 
osteoclast differentiation.   
TBT’s effect on bone has been primarily investigated in the context of PPARγ 
agonism.(57) Although TBT also binds and activates RXRα with greater affinity than it 
does PPARγ,(63) the role of TBT as an RXRα agonist in bone that is capable of activating 
RXR:RXR homodimers and other RXRα heterodimers (e.g. RXRα:LXR) has received 
less attention.(81,238,240) We confirmed TBT’s activation of RXR and LXR target genes 
(previously shown in osteoblast(81) and osteoclast(238) cell lines) in whole bone and 
primary osteoclast cultures, and show that it activates a pathway relevant to 
osteoclastogenesis, namely the expression of Mafb. This gene has been shown to be a 
target of RXR:RXR homodimers in osteoclast precursors and required for osteoclast 
differentiation.(13) In maturing osteoclasts, Mafb is indirectly upregulated by 
RXRα:LXRα activation via increased expression of SREBP1c, which suppresses 
osteoclast maturation.(13) The TBT-induced upregulation of Mafb is consistent with the 
decreases in Nfatc1 transcript levels. TBT could be increasing Mafb via RXRα 
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homodimers, RXRα:LXR heterodimers, or both. However, it is notable that the increase 
in Mafb seen with TBT in vitro more closely reflects that of the RXR homodimer agonist 
LG100268 rather than the LXR agonist T0901317 (Figure 3.6). 
Both the LXR and RXR have been proposed as targets for interventions to combat 
low bone density, given their roles in moderating osteoclast differentiation.(13,234,237) To 
our knowledge, these are the first results to demonstrate an association between RXR or 
LXR agonism and increased bone density in intact, adult mice rather than 
ovariectomy(234) or inflammation-induced(235) models of bone loss. The results also show 
for the first time that TBT’s role as a bone suppressive agent is dependent upon the level 
of coupled remodeling that occurs as a given bone site. Use of TBT as a multi-functional 
model compound in conjunction with the appropriate Cre-lox knockout models may 
provide important insights into the relative contributions of different nuclear receptors in 
determining the balance of bone resorption and formation.  
We observed a unique phenotype in the long bones of female C57Bl/6J mice after 
being treated with TBT. Despite an apparent slowing of bone apposition in the cortical 
shell at mid-diaphysis, exposure to TBT resulted in a greater mineral content in the 
trabecular space compared to Vh-treated controls. We found that that the prevalence of 
osteoclasts in the trabecular space was not attenuated. Rather, the preponderance of bone 
formation appears to be a result of augmented osteoclast function, in particular 
osteoclast-osteoblast signaling favoring osteoblastogenesis. Future studies will determine 
the overall pattern of bone growth over the course of TBT treatment and more precisely 
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characterize the role of RXRα in activating multiple nuclear receptor-mediated pathways 
in bone. 
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Figures 
FIGURE 3.1.  TBT suppresses osteogenic differentiation pathway and 
mineralization markers more potently and efficaciously in female-derived cultures 
compared to male-derived cultures. 
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Figure 3.1. TBT suppresses osteogenic differentiation and mineralization more 
potently and efficaciously in female-derived compared to male-derived cultures. 
BM-MSCs were harvested from 9-week old female and male, C57Bl/6J mice, cultured in 
the presence of osteogenic media and treated with Vh (DMSO) or TBT (10 nM, 50 nM) 
for 7 (gene expression) or 10 (phenotype markers) days.  a.) Relative mRNA expression 
of osteoblast/osteocyte differentiation markers Runx2, Osx, and Dmp1. b.) Alkaline 
phosphatase activity (left), nodule count (center) and mineralization (right). Data are 
presented as mean ± SE. n=4–5 independent cultures. *p < 0.05, **p<0.01, Two-way 
ANOVA (Sidak’s multiple comparison test),  
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FIGURE 3.2.  TBT reduces diaphysis cross-sectional area and cortical thickness 
while increasing trabecular structure in female C57Bl/6J femurs. 
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FIGURE 3.2.  (cont.) 
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Figure 3.2. TBT reduces diaphysis cross-sectional area and cortical thickness while 
increasing trabecular structure in female C57Bl/6J femurs. 12-week old female wild 
type C57Bl/6J mice were treated with sesame oil (Vh) (n=12) or 10 mg/kg TBT (n=11) 
via oral gavage for 10 weeks. a.) Representative micro-CT images of mid-diaphysis. 
Scale bar = 400 µm. b.) Cortical bone parameters. Ct.Th: cortical bone thickness; Ct.Ar: 
cortical bone area; Ma.Ar: medullary (marrow) area; Tt.Ar: total cross-sectional area; 
Ct.Ar/Tt.Ar: cortical area fraction; mineral density. c.) Representative micro-CT images 
of distal metaphysis. Scale bar = 400 µm. d.) Trabecular bone parameters. BV/TV: bone 
volume fraction; mineral density; Conn.D: connectivity density; Tb.N: trabecular 
number; Tb.Sp: mean trabecular spacing; Tb.Th: mean trabecular thickness. Data are 
presented from individual mice, and the mean is indicated by a line. n=11–12 individual 
mice. **p < 0.01, *** p < 0.0001 unpaired t-test.  
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FIGURE 3.3.  In vivo TBT exposure increases both trabeculae and marrow 
adipogenesis.  
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Figure 3.3. In vivo TBT exposure increases both trabeculae and marrow 
adipogenesis. Mice were treated as described in Figure 3.2. a.) Representative images of 
5 µm slices of distal femur (n=4 Vh, 5 TBT) stained with hematoxylin and eosin 
(adipocytes indicated by red arrows). b.) Adipocyte count per bone section (1.5 mm from 
growth plate). Whole humerus bone mRNA expression (n = 12 Vh, 11 TBT 10 mg/kg) of 
c.) the adipocyte marker, perilipin (Plin1), d.) osteoblast (Runx2, Osx) and osteocyte 
(Dmp1) differentiation markers, and e.) the osteocyte signaling protein Sost. Data are 
presented as mean ± SE. *p < 0.05, **p < 0.01, Mann-Whitney. 
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FIGURE 3.4.  In vivo TBT exposure modifies osteoclast gene expression without 
influencing osteoclast cell number.
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Figure 3.4. In vivo TBT exposure modifies osteoclast gene expression without 
influencing osteoclast cell number. Mice were treated as described in Figure 3.2. a.) 
Representative images of 5 µm slices of distal femur stained for TRAP (red shading; n=4 
Vh, 5 TBT). b.) Oc/B.Per.: number of TRAP-positive osteoclasts per nm of trabecular 
perimeter, excluding cortex. Trab. Perimeter: total perimeter of trabecular bone (um). c.) 
Quantification of serum TRAP by ELISA (n = 12 Vh, 11 TBT 10 mg/kg). Whole 
humerus bone mRNA expression (n = 12 Vh, 11 TBT 10 mg/kg) of d.) Osteoclast 
differentiation markers Nfatc1, Apc5 and Ctsk, and e.) Intercellular communication 
proteins Rankl/Opg (osteoblast to osteoclast) and Ct1 (osteoclast to osteoblast). Data are 
presented as mean ± SE. *p < 0.05 **p < 0.01, Mann-Whitney.  
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FIGURE 3.5.  TBT suppresses differentiation and functional gene expression but 
does not change osteoclast cell number in vitro.
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FIGURE 3.5.  (cont.) 
 
 
 
 
 
  
d .
Vh TBT 20 nM
0
2 0
4 0
6 0
8 0
1 0 0
T ra p +  c e ll  c o u n ts
T
r
a
p
+
, 
M
u
N
C
/w
e
ll
V h 2 0 5 0 8 0
T B T
(nM )
0
1 0
2 0
3 0
A v g . C o u n t
#
 o
b
je
c
ts
/f
ie
ld
V h 2 0 5 0 8 0
T B T  (n M )
* *
0
1
2
3
4
5
%  area
%
 r
e
s
o
r
b
e
d
 s
u
r
fa
c
e
/f
ie
ld
V h 2 0 5 0 8 0
T B T  (n M )
* p  =
0 .0 6 4
0
5
1 0
A v g . S iz e
m
m
2
V h 2 0 5 0 8 0
T B T  (n M )
e .
f.
TBT 50 nM TBT 80 nM
109 
 
 
1
0
9
 
Figure 3.5. TBT suppresses differentiation and functional gene expression but does 
not change osteoclast cell number in vitro. Primary bone marrow macrophages were 
isolated from 9-week-old, female C57BL/6J mice, induced to differentiate to osteoclasts 
with M-CSF and RANKL (see Methods), and after 24 hrs treated with Vh (DMSO) or 
TBT at indicated concentrations for 6 days. mRNA expression of a.) Osteoclast 
differentiation (Nfatc1, Acp5) and functional markers (Ctsk), and b.) Osteoclast signaling 
molecules Ct-1 and Sema4d, c.) Representative images of TRAP-positive, multinucleated 
(3 or more nuclei) cells (Scale bar = 400 µm). d.) Average number of TRAP-positive, 
multinucleated cells per well (n=4 separate experiments). e.) Average number of 
resorption pits per field of view, percent of mineral surface area covered by resorption 
pits, and average size of resorption pits (excluding pits < 1,100 µm2). f.) Representative 
images of resorption pits, following thresholding for image analysis (resorption pits in 
red, scale bar = 400 µm). n=5–7 independent cultures.  Data are presented as mean ± SE. 
*p < 0.05, **p < 0.01 compared to Vh, one-way ANOVA (Dunnett’s). 
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FIGURE 3.6.  TBT activates RXR and LXR-dependent pathways in whole bone and 
in vitro osteoclast culture. 
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Figure 3.6. TBT activates RXR and LXR-dependent pathways in whole bone and in 
vitro osteoclast culture. a.) Mice were treated as described in Figure 3.2. Whole humerus 
bone mRNA expression of LXR-dependent genes Abca1, Srebp1c, and the RXR-
dependent gene Mafb. Data are presented as mean ± SE. n = 11–12 individual mice. 
**p<0.01, Mann-Whitney b.) Osteoclasts cultures were prepared as described in Figure 
3.5 and treated with Vh (DMSO), TBT (20, 50, or 80 nM), rosiglitazone (PPARγ agonist, 
100 nM), LG100268 (LG268, RXRα agonist, 100 nM), or T0101317 (T317, LXRα/β 
agonist, 100 nM) for 6 days. mRNA expression  of LXR- and RXR-dependent genes. 
Data are presented as mean ± SE. n=6 independent cultures. *p<0.05 **p<0.01 compared 
to Vh, one-way ANOVA (Dunnett’s). TBT treatments were compared to Vh separately 
from control comparisons.  
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Supplemental materials 
Supplementary Table S3.1. List of primers used for qPCR. 
Primer Manufacturer Sequence/Catalog # 
Abca1 IDT F: CTTCCCACATTTTTGCCTGG 
R: AAGGTTCCGTCCTACCAAGTCC 
Acp5 IDT F: CCATTGTTAGCCACATACGG 
R: ACTCAGCACATAGCCCACAC 
B2m IDT F: CTGCTACGTAACACAGTTCCACCC 
R: CATGATGCTTGATCACATGTCTCG 
Ct1 IDT F: GGAGGGAAGTCTGGAAGACC 
R: TGTTGCTGCACGTATTCCTC 
Ctsk IDT F: GTTGTATGTATAACGCCACGGC 
R: CTTTCTCGTTCCCCACAGGA 
Dmp1 IDT 
 
Qiagen 
F: CAACTGGCTTTTCTGTGGCAA 
R: TGGGTGCGCTGATGTTTGCT 
Cat # QT01078210 
Lxra IDT F: GAGTTGTGGAAGACAGAACCTCAA 
R: GGGCATCCTGGCTTCCTC 
Lxrb IDT F: CCCCACAAGTTCTCTGGACAC 
R: TGGCGGAGGTACTGGGC 
Mafb IDT F: CGCGTCCAGCAGAAACATC 
R: AGCTGCTCCACCTGCTGAAT 
Nfatc1 IDT F: CCCTTTAAAAATGAGGACAATAGCTTT 
R: TTGCTGCCCTTTCACTGATG 
Opg IDT F: TTGCCTGGGCTGCAGAGACG 
R: CCAGGAGCACCAGGAGTGCG 
Osx 
 
Qiagen Cat # QT00293181 
Plin1 IDT F: GGGACCTGTGAGTGCTTCC 
R: GTATTGAAGAGCCGGGATCTTTT 
Rankl IDT F: GCTGGGCCAAGATCTCTAAC 
R: GTAGGTACGCTTCCCGATGT 
Rn18s IDT 
 
Qiagen 
F: GTAACCCGTTGAACCCCATT 
R: CCATCCAATCGGTAGTAGCG 
Cat # QT01036875 
Runx2 IDT 
 
Qiagen 
F: TTTAGGGCGCATTCCTCATC 
R: TGTCCTTGTGGATTAAAAGGACTTG 
Cat # QT00102193 
Sema4D IDT F: CCTGGGAACATGGAGAGGTA 
R: GGGCGCCTACATACAGAGTG 
Sost IDT F: GCCTCATCTGCCTACTTGTG 
R: CTGTGGCATCATTCCTGAAG 
Srebp1c IDT F: GGAGCCATGGATTGCACATT 
R: GGCCCGGGAAGTCACTG 
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Supplementary Figure S3.1 
 
Figure S3.1. 10 mg/kg TBT via oral gavage does not cause overt systemic toxicity in 
vivo. 12 week old female C57Bl/6J mice were treated with either vehicle (Vh, sesame oil, 
10 µg/L) or TBT (10 mg/kg bw in sesame oil) via oral gavage 3x/week for 10 weeks 
(n=12 for both groups). Body weight was measured at each dosing. a.) Percent change in 
body weight (g) from first weekly average and last weekly average. b.) Thymus weight as 
a percentage of body weight at euthanasia. n=11 Vh (1 thymus discarded due to 
dissection error), n=12 TBT. **p<0.01, unpaired t-test. 
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Supplementary Figure S3.2 
 
Figure S3.2. TBT does not cause overt toxicity at concentrations used in vitro. 
Primary bone marrow cells were isolated from 12 week old female C57Bl/6J mice and 
allowed to differentiate with MCSF (naïve) or MCSF and RANKL (see Methods). The 
MSC medium was replaced, and the cultures were treated with Vh (DMSO, 0.1%) or 
TBT (20, 50, 80 nM, 2 µM) and incubated for 5 days. a.) Cellularity was assessed by 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) labeling for 3 hrs by 
standard methods. b.) Necrosis was assessed by measuring dead cell protease release 
(CytoTox-Glo™ Cytotoxicity Assay, Promega). Absorbance and luminescence in 
experimental wells was normalized by dividing by that measured in naive wells. Data are 
presented as means ± SE of 4 independent bone marrow preparations. A 2hr treatment 
with 2 μM TBT was used as a positive control.  
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Supplementary Figure S3.3 
 
Figure S3.3. TBT activates LXR-dependent pathways in BM-MSCs. Primary bone 
marrow cells were isolated from 9 week (n=3) and 12 week (n=3) female C57Bl/6J mice 
and allowed to differentiate for 7 days. The media was replaced with osteogenic media 
(see Methods) and either Vh (DMSO, 0.1%) or TBT (10, 50 nM). After 7 days, total 
RNA was harvested for relative gene expression with qPCR. Relative gene expression 
was determined using the Pfaffl method to account for differential primer efficiencies.(223) 
The average Cq value for 18s ribosomal RNA (Rn18s) and beta-2-microglobulin (B2m) 
was used for normalization. The Cq value for naïve, undifferentiated cultures was used as 
the reference point, and the data are reported as “Fold Change from Naive.” * p<0.05, 
ANOVA (Dunnett’s).  
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Abstract 
The vast array of potential environmental toxicant combinations necessitates the 
development of efficient strategies for predicting toxic effects of mixtures. Current 
practices emphasize the use of concentration addition to predict joint effects of endocrine 
disrupting chemicals in co-exposures. Generalized Concentration Addition (GCA) is one 
such method for predicting joint effects of co-exposures to chemicals and has the 
advantage of allowing for mixture components to have differences in efficacy (i.e., dose-
response curve maxima). PPARγ is a nuclear receptor that plays a central role in 
regulating lipid homeostasis, insulin sensitivity, and bone quality and is the target of an 
increasing number of environmental toxicants. Here, we tested the applicability of GCA 
in predicting mixture effects of therapeutic (rosiglitazone and non-thiazolidinedione 
partial agonist) and environmental PPARγ ligands (phthalate compounds identified using 
EPA’s ToxCast database). Transcriptional activation of human PPARγ1 by individual 
compounds and mixtures was assessed using a PPRE-driven luciferase reporter. Using 
individual dose-response parameters and GCA, we generated predictions of PPARγ 
activation by the mixtures, and we compared these predictions to the empirical data. At 
high concentrations, GCA provided a better estimation of the experimental response 
compared to three alternative models: Toxic Equivalency Factor, Effect Summation and 
Independent Action. These alternatives provided reasonable fits to the data at low 
concentrations in this system. These experiments support the implementation of GCA in 
mixtures analysis with endocrine disrupting compounds and establish PPARγ as an 
important target for further studies of chemical mixtures.  
118 
 
 
1
1
8
 
Introduction  
Exposure to chemicals is rarely on a single-chemical basis, requiring risk 
assessments to address chemical mixtures. Because testing all mixture combinations is 
experimentally impossible, risk assessors and toxicologists employ models that predict 
mixture effects from minimal data that may vary chemical-to-chemical, such as dose-
response curves characterizing a compound’s potency (e.g. EC50) and efficacy (maximum 
response) when acting on a specific biological target.  
Current chemical mixtures analysis for endocrine disrupting compounds 
emphasize concentration addition (also called dose addition),(251) whereby individual 
component concentrations producing a given mixture effect are scaled by their proportion 
in the mixture and summed (for example, see Rajapakse et al. (2001)).(252) This method is 
generally preferred for chemicals that act by similar mechanisms over models such as 
Independent Action or Effect Summation. For example, concentration addition may be 
applicable in cases of mixtures with components that act via the same molecular pathway, 
such as mixtures of dioxin-like polychlorinated biphenyls (PCBs) that act through the 
aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor with one ligand-
binding site. 
Toxic equivalency factor (TEF) is a special case of concentration addition 
whereby the relative potency of a mixture component is used to generate an equivalent 
dose of a well-characterized reference compound.(253) In cases where the dose-response 
curves of all the components differ only in potency (same shape and maximal effect), 
TEFs are generated by comparing the potency of each component to a reference 
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compound, e.g., 2,3,7,8-TCDD for the dioxin-like compounds.(253) TEF uses the toxic 
equivalencies to calculate an equivalent total dioxin dose. The effect of the mixture is 
then calculated from the dose-response curve of dioxin. This model has the advantage of 
easy interpretation and implementation where reference chemical data are available, but 
crucially relies on the assumption that the dose-response curves of component chemicals 
differ only in potency; the assumptions for use of TEFs are violated when compounds 
differ in efficacy.  
Howard and Webster (2009) introduced Generalized Concentration Addition 
(GCA) to allow for differences in efficacy among mixture components.(254) This model 
uses inverse mathematical functions allowing for some components to have submaximal 
efficacy. They demonstrated the utility of this model toward a mixture of AhR agonists 
with different efficacies.(255) GCA accurately fit the experimental data of a full and a 
partial AhR agonist mixture, whereas TEF did not predict the competitive effect of a 
partial agonist at high concentrations in a mixture. 
Current research has identified peroxisome proliferator-activated receptor gamma 
(PPARγ) as an important target molecule in endocrine disruption and developmental 
biology. PPARγ is a nuclear receptor that acts as a metabolic sensor and forms an 
obligate, permissive heterodimer with the retinoid X receptor alpha (RXRα).(27) As the 
list of environmental toxicants that activate PPARγ grows in number and structural 
variety,(64,66–68,256) there is increasing concern over the influence of environmental 
chemical exposure on PPARγ-related endpoints, namely lipid homeostasis (for review 
see Feige et al., 2006),(257) obesity,(61,258) and bone homeostasis.(15,80,81,239) The extent of 
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exposures and toxicological importance of PPARγ ligands further support the need for 
the development of flexible models to predict mixture effects.  
Here, we tested the applicability of GCA in modeling mixture effects of full and 
partial PPARγ agonists and compared GCA’s performance against the TEF, Independent 
Action (IA) and Effect Summation (ES) models. IA and ES are arguably inappropriate 
here: IA is intended to be applied when compounds act by different modes of action, 
while ES is generally considered inappropriate by mixtures toxicologists.(259) However, 
investigators do not always know the mechanism of action and it is not always clear how 
similar mechanisms need to be for CA to apply.(260) It is therefore useful to see how these 
different models compare with GCA. 
Using human PPARγ1 and RXRα and a PPRE response element-dependent 
luciferase reporter, we generated dose-responses for individual ligands. We predicted 
mixture effects using the different additivity models, and compared these predictions with 
experimental mixture results. We establish GCA as a model for predicting mixture effects 
of synthetic PPARγ agonists and show it to be a reasonable additive model of PPARγ 
activation by mixtures, including therapeutic drugs and phthalates that we identified as 
PPARγ agonists from the ToxCast data set.  
 
Materials and Methods 
Chemical Suppliers 
Rosiglitazone was obtained from Cayman Chemicals (Ann Arbor, MI). 
Nonthiazolidinedione partial agonist (nTZDpa) was from Tocris Biochemicals (Bristol, 
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UK). Di-(2-ethylhexyl) phthalate (DEHP), mono-(2-ethylhexyl) phthalate (MEHP), 
mono-butyl phthalate (MBP), butyl-benzyl phthalate (BBP), and mono-benzyl phthalate 
(MBzP) were obtained from Sigma (St. Louis, MO).  
 
Reporter Assay 
Cos7 cells were plated in 96-well plates and transiently transfected with human 
PPARG1 (provided by V.K. Chatterjee, University of Cambridge, Cambridge, UK) and 
human RXRΑ (plasmid 8882, Addgene, Cambridge, MA)(27) expression vectors, with 
peroxisome proliferator response element 3x-TK-Luc (plasmid 1015, Addgene)(224) and 
cytomegalovirus-enhanced green fluorescent protein reporter using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA). After overnight incubation at 37C, the media was replaced 
and cells received no treatment (medium only), Vh (dimethyl sulfoxide, 0.1%), or PPARγ 
ligands at a range of concentrations either alone or in combination (rosiglitazone 1 x 10-10 
M – 1 x 10-6 M; nTZDpa 1 x 10-9 M – 5 x 10-6 M; DEHP 1 x 10-7 M – 2 x 10-4 M; MEHP 
1 x 10-7 M – 1 x 10-4 M; BBP 1 x 10-7 M – 5 x 10-4 M; MBP 1 x 10-7 M – 5 x 10-4 M; 
MBzP 1 x 10-7 M – 5 x 10-4 M). Concentrations of individual chemicals were chosen 
using pilot studies designed to identify the highest, non-toxic dose. After 24h of 
treatment, cells were lysed with GloLysis buffer and mixed with BrightGlo Luciferase 
buffer (Promega Inc., Madison, WI). Luminescence and fluorescence were determined 
using a Synergy2 plate reader (Biotek Inc., Winooski, VT). Luminescence of each well 
was normalized to green fluorescent protein fluorescence, and the resulting values were 
normalized to medium-only wells to obtain fold change in PPARγ activation.   
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ToxCast PPARγ agonist identification 
ToxCast assay and chemical data were downloaded from EPA’s ToxCast portal 
(http://www2.epa.gov/chemical-research/toxicity-forecaster-toxcasttm-data) in May of 
2015. Chemicals were selected for inclusion that showed dose-response data fit with a 
monotonic Hill function in the Attagene PPRE_cis_up assay and the Attagene 
PPARγ_trans_up assays. To limit the selection to chemicals that did not also activate 
RXRα, these candidates were limited to those that fit RXRα-specific assays Odyssey 
Thera NURR1_NURR1RXRa_1440, Attagene RXRa_TRANS_up, and Odyssey Thera 
NURR1_NURR1RXRa_0480 with a constant (i.e. no response) model. Of the resulting 
88 chemicals from this screening process, we identified five phthalates for testing, two 
parent phthalate compounds (di-ethyl hexyl phthalate (DEHP) and butyl-benzyl phthalate 
(BBP)) and three phthalate metabolites (mono-ethyl hexyl phthalate (MEHP), mono-
butyl phthalate (MBP), and mono-benzyl phthalate (MBzP)).  
 
Experimental Fits 
GCA requires specification of mathematical dose response functions that are 
invertible yielding real numbers for all effect levels of interest. As in our previous 
work,(255) we chose the function based on a biologically-based model for binding of a 
ligand to a receptor at a single binding site followed by activation, where the degree of 
activation can depend on the ligand; the compounds we are investigating bind PPARγ, 
not RXRα. This model yields Hill functions with a Hill coefficient of 1. Individual 
chemical dose-response data were therefore fit to the following equation: 
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 f([A]) = min + (max-min)([A])/(KA+ [A])      (1) 
 
where KA is the macroscopic equilibrium constant for agonist A (EC50, equal to the dose 
producing a 50% maximal effect), min and max are the curve minimum and maximum 
effect levels, respectively, and [A] is the dose of ligand A. For mixtures experiments, data 
points were adjusted by subtracting the response value of Vh-only treated wells, allowing 
the curves to be fit with a two-parameter Hill function: f([A]) = αA([A])/(KA + [A]), where 
αA is the maximum effect level.  
 
Toxic Equivalency Factor (TEF) 
TEF is a special case of concentration addition (and GCA) requiring parallel dose-
response curves, including the same efficacy. When efficacies differ, TEFs will not in 
principle work. However, relative potencies may still be computed and may provide 
approximate answers in some cases,(255) though results will depend on the choice of 
reference compound and its efficacy. For a reference compound, we used rosiglitazone, 
the compound with the highest potency and efficacy, and traditionally used as a positive 
control for PPARγ activity. The relative potency (γi) is determined by γi =KA/Ki, where A 
is the reference compound rosiglitazone. The total effect of the mixture, estimated for n 
components, is: 
 
𝐸𝑇𝐸𝐹 = 𝑓𝐴([𝐴] + ∑ 𝛾𝑖
𝑛
𝑖=1 [𝑋𝑖]) =
𝛼𝐴([𝐴]+∑ 𝛾𝑖
𝑛
𝑖=1 [𝑋𝑖])
𝐾𝐴+ ([𝐴]+∑ 𝛾𝑖
𝑛
𝑖=1 [𝑋𝑖])
     (2) 
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Generalized Concentration Addition (GCA) 
GCA relaxes the requirement of equal dose-response maxima. The general GCA 
equation for n components is: 
 
1 =  ∑
[𝑋𝑖]
𝑓𝑖
−1(𝐸)
 𝑛𝑖=1          (3) 
 
where  is the mathematical inverse of the individual chemical dose-response 
function and E is the mixture effect level. The inverse of the two-parameter Hill function 
above is , a function which yields real numbers for positive values of 
αi, Ki and E. Substituting this equation into (3) allows for easy calculation of the effect 
level at a given mixture of n components with efficacies αi and EC50s given by Ki: 
 
𝐸𝐺𝐶𝐴 = 𝑓𝑚𝑖𝑥𝑡𝑢𝑟𝑒([𝑋1], … , [𝑋𝑛]) =  
∑
𝛼𝑖[𝑋𝑖]
𝐾𝑖
𝑛
𝑖=1
1+ ∑
[𝑋𝑖]
𝐾𝑖
𝑛
𝑖=1
      (4) 
 
While (3) is the general definition of GCA, the form of (4) also depends on the specific 
dose-response function being modeled and may not apply more generally. 
 
Effect Summation (ES) and Independent Action (IA) 
ES and IA are response-additive models that sum the individual responses, rather 
than the doses, of the mixture components. For ES 
 
fi
-1(E)
fi
-1(E)= EKi / (a1 -E)
125 
 
 
1
2
5
 
𝐸𝐸𝑆 = 𝑓𝑚𝑖𝑥𝑡𝑢𝑟𝑒([𝑋]1, … [𝑋]𝑖) =  ∑ 𝑓𝑖([𝑋]𝑖)
𝑛
𝑖=1      (5) 
 
IA is generally used for compounds that act by different mechanisms. IA assumes that 
compounds have the same maximal effect of one:  
 
𝐸𝐼𝐴 = 𝑓𝑚𝑖𝑥𝑡𝑢𝑟𝑒([𝑋]1, … [𝑋]𝑖) = 1 − ∏ (1 − 𝑓𝑖([𝑋]𝑖))
𝑛
𝑖=1
 
 
When efficacies differ, the standard formula needs to be modified, and the best procedure 
is not clear. Following Payne et al (2001),(261) we scaled the response of individual 
components to the maximum efficacy, αmax , then scaled the overall results to the same 
maximum: 
 
𝐸𝐼𝐴 = 𝑓𝑚𝑖𝑥𝑡𝑢𝑟𝑒([𝑋]1, … [𝑋]𝑖) = 𝛼𝑚𝑎𝑥 (1 − ∏ (1 −
𝑓𝑖([𝑋]𝑖)
𝛼𝑚𝑎𝑥
)𝑛𝑖=1 )   (6) 
 
The estimated maximum efficacy here was for MBzP, 7% larger than that of 
rosiglitazone (Figure 4.3b). Scaling components by their own maximums (αi) produces 
predictions that are larger and closer to those provided by the TEF model (data not 
shown). 
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Statistics and software 
Individual dose-response curves were fit and relevant parameters were estimated 
using Prism (version 6, GraphPad). Combination dose-response surfaces were generated 
in R using the wireframe() function. The R code for generating the additive model 
predictions is available at the Boston University Superfund Research Program website 
(www.busrp.org). Model extrapolations were performed in Mathematica (version 9.0.1.0, 
Wolfram Alpha). Differences in experimental distributions and model predicted 
distributions were tested using the non-parametric Wilcoxon Rank Sum and 
Komolgorov-Smirnov tests.  
 
Results 
We began by establishing the dose-responses of two synthetic PPARγ ligands, 
rosiglitazone (full agonist) and nTZDpa (partial agonist). Cos-7 cells were transfected 
with expression vectors for human RXRα and PPARγ1 and a luciferase reporter gene 
under transcriptional control of a PPRE response element; cells were treated with each 
chemical separately and in combination. As shown in Figure 4.1a, the individual dose 
response data were well fit by Hill functions with a Hill coefficient of 1 (the “S” shape of 
the data in the figure is partly due to plotting concentration on the log scale). nTZDpa and 
rosiglitazone stimulate PPARγ activation with similar potencies (EC50s of 2.2 x 10-8 M 
and 7.1 x 10-8 M, respectively), which were comparable to established estimates (4.3 x 
10-8 M for,(30) 5.7 x 10-8 M for nTZDpa(262)). nTZDpa is a significantly less efficacious 
PPARγ ligand, with a response maximum of only ~17% of rosiglitazone (Figure 4.1a). A 
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PPARγ-dominant negative construct suppresses luciferase gene expression stimulated by 
rosiglitazone in this system,(263) indicating that the increased luminescence as a function 
of concentration is due specifically to PPARγ binding and activation by the agonists.  
We hypothesized that mixtures of rosiglitazone and nTZDpa would show a 
reduction in overall PPARγ activation at effect levels above the efficacy of nTZDpa, 
owing to the behavior of a partial agonist to act in the manner of a competitive antagonist 
in a mixture. Figure 4.1b demonstrates that at high effect levels, the response to 
rosiglitazone is antagonized and the overall activation of PPARγ by the mixture 
decreases: note that the 1 x 10-11 nTZDpa curve (solid line, black circles) closely 
approximates the rosiglitazone curve in 1a, but increasing concentrations of nTZDpa 
reduce the curve closer to that of nTZDpa in Figure 4.1a. These data support the 
conclusion that nTZDpa is outcompeting rosiglitazone for PPARγ binding and that a 
higher proportion of partial agonist-bound receptors is attenuating the overall effect. 
To compare the empirical dose response data with those predicted by different 
additive models, three-dimensional response surfaces of PPARγ activation by the 
rosiglitazone/nTZDpa combinations were plotted (Figure 4.2). Marginal (i.e. individual) 
dose-response curves lie along the front edges of the box (in bold) and combination 
effects comprise the interior surface. The antagonistic effect of nTZDpa is evident in the 
dose response surface, with the surface dropping downward at high concentrations of 
nTZDpa and rosiglitazone (Figure 4.2a). Using individual-chemical fit parameters (listed 
in the embedded table in Figure 4.2), we generated predicted response surfaces under 
different additive models (ES, TEF, IA and GCA).  
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The effect summation (ES) model, generated from equation 5, sums the individual 
effect levels of each combination of rosiglitazone and nTZDpa. At low concentration 
combinations, the ES surface approximates the empirical surface (Figure 4.2b). However, 
at high concentration combinations, the modeled surface implies supra-maximal 
activation, as the effect of nTZDpa is added to the effect of rosiglitazone.  
Independent Action (IA, equation 6), assumes the observed individual effects 
result from independent mechanisms of action. Like ES, at low concentrations the model 
approximates the empirical surface (Figure 4.2c). Higher concentration combinations 
begin to show the characteristic competitive antagonism effect of the full and partial 
ligand mixture, but the model fails to fully capture the reduction in overall effect.  
Toxic Equivalency Factor (TEF), defined in equation 2, assumes that the 
efficacies of rosiglitazone and nTZDpa are equal, and that nTZDpa is a diluted form of 
the more potent rosiglitazone. The modeled response surface generated by TEF shows no 
antagonistic effect of nTZDpa at high concentrations (Figure 4.2d).  
Because GCA was formulated to allow for differences in efficacy among mixture 
components,(254) we hypothesized that the surface generated by GCA would most 
accurately resemble the empirical surface. The GCA-modeled surface (equation 4) 
captures the attenuating effect of high concentrations of nTZDpa (Figure 4.2e). The non-
parametric Wilcoxon Rank Sum and Komologorov-Smirnov tests indicate that the 
distribution of GCA-modeled estimates is not significantly different from empirical 
results (p > 0.05), whereas the TEF and ES distributions do differ significantly from the 
experimental data (p < 0.01 for both comparisons). Generation of modeled distributions 
129 
 
 
1
2
9
 
using the upper and lower bounds of the experimental standard errors resulted in minimal 
changes to the modeled estimates (Supplementary Figure S4.1). From these results, we 
concluded that GCA is a viable model for predicting combination effects of two PPARγ-
specific agonists that have different efficacies.  
Next, we tested the applicability of GCA in modeling PPARγ activation 
stimulated by mixtures of environmental ligands. From EPA’s ToxCast data set, we 
identified potential PPARγ agonists, including five phthalate compounds: di-ethyl hexyl 
phthalate (DEHP), butyl-benzyl phthalate (BBP), mono-ethyl hexyl phthalate (MEHP), 
mono-butyl phthalate (MBP), and mono-benzyl phthalate (MBzP). Individually, all but 
DEHP activated PPARγ in our assay. Table 1 lists the efficacy (as maximum-minimum) 
and potency (EC50) derived from the dose-response curve of each parent (Figure 4.3a) 
and metabolite (Figure 4.3b) compound. Though the potencies were mostly within the 
same order of magnitude (with MBzP being slightly less potent than the other phthalates), 
the efficacies varied roughly 4-fold between the least (MBP) and most efficacious 
(MBzP).       
We began by testing an array of rosiglitazone (full agonist) and MEHP (partial 
agonist) combinations. Similar to rosiglitazone and nTZDpa mixtures, MEHP increases 
PPARγ activation at low effect levels (left side of Figure 4.3c), but antagonizes the 
PPARγ activation stimulated by rosiglitazone at higher effect levels, reducing the mixture 
activation of PPARγ to the response maximum of MEHP (right side of Figure 4.3c). The 
predictions of GCA fit the observed data somewhat better than the TEF model at high 
dose combinations where a small amount of antagonism by MEHP becomes evident 
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(Figure 4.3d, 4.3e and 4.3f). The difference between the two models is not as stark as that 
for the rosiglitazone/nTZDpa mixture (Figure 4.2). The reason is that the estimated 
efficacy for MEHP is 80% that of rosiglitazone, far closer in maximal effect compared to 
nTZDpa. 
Next, we tested a complex mixture of phthalates. We hypothesized that, given the 
different efficacies among the phthalates, GCA would again provide the most accurate fit, 
while the response-additive models and TEF would overestimate the mixture effect. To 
test this hypothesis, we constructed two mixtures of multiple phthalates. Because of the 
logistical complication of testing mixtures with more than two components, we used ray 
designs in which each component is in constant proportion to one another across mixture 
dilutions. We excluded DEHP from the rays because of its lack of activity in the PPARγ 
activation assay. The starting solution for the first ray (A) consisted of BBP, MEHP, 
MBP, and MBzP at concentrations just below their respective EC10 values, as determined 
by their individual dose-responses (Table 4.2). The starting solution for the second ray 
(B) combined the four phthalates at concentrations that produced the same effect level as 
10% of rosiglitazone’s maximum effect (Table 4.2). Each mixture was diluted by factors 
of 2, 5, 10, 20, 50, and 100, and the dilution series were applied in the PPARγ activation 
assay. Using the individual dose response parameters listed in Table 4.1, mixture 
responses also were predicted using the ES, TEF, GCA, and IA models.  
The starting concentrations of mixtures A and B produced effect levels that were 
7% and 30% higher, respectively, than the predicted individual effect of the most 
efficacious component (MBzP) at the concentration at which it was added to each 
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mixture (1.6 x 10-5 M, Table 2). By the second and fourth dilutions of ray A and B, 
respectively, the activation of PPARγ by the mixture was indistinguishable from baseline 
(Figure 4.4a and 4.4b). At low concentrations, all four models — GCA, TEF, ES and IA 
— adequately fit the empirical data. At higher concentrations, the TEF predictions 
strongly diverge from the observed data, while GCA may provide a slightly better fit than 
ES and IA. Figure 4.4c provides a closer comparison of the starting mixture 
concentrations and the modeled values. 
To examine the behavior of these models at high concentrations, we used the 
same fitting parameters to extrapolate models to high dose levels for ray A. As shown by 
Figure 4.5, the models diverge with increasing mixture dose. At high mixture doses, the 
ES model vastly exceeds the other models. Both the TEF and IA models overestimate 
effects compared to GCA; this occurs in part because only GCA takes into account the 
antagonistic effect of partial agonists. 
 
Discussion 
Current methods for estimating risk from chemical exposure predominately focus 
on single chemical exposure instead of the more realistic scenario of co-exposure to 
multiple chemicals. At the same time, several agencies are recognizing the need to focus 
research on low dose exposures to endocrine disrupting chemicals that act via 
inappropriate activation of nuclear receptors.(70,264,265) One such nuclear receptor is 
PPARγ, which plays a central role in toxic mechanisms related to lipid homeostasis, bone 
quality, and other endpoints (for review, see Ahmadian et al., 2013).(266) Given its status 
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as a target of endocrine disruption by a variety of environmental agonists, PPARγ is an 
important model for which to study chemical co-exposures and develop ways to predict 
toxicity of chemical mixtures. Here, we established the utility of Generalized 
Concentration Addition (GCA)(254) in modeling joint effects of chemical co-exposures 
that activate PPARγ. 
The experimental design used to generate experimental mixture data and test the 
additive models was similar to that of Howard et al. (2010),(255) who used GCA to model 
mixture effects of aryl hydrocarbon receptor (AhR) agonists. In that study, they showed 
experimentally that the partial AhR agonist (galangin) could decrease the overall mixture 
effect when combined with a full AhR agonist (PCB126). This effect of galangin 
resembled that of a competitive antagonist. The difference is that a partial agonist 
increases the mixture effect at levels below its efficacy, but decreases the mixture effect 
at levels above its efficacy.  
We began by testing the utility of GCA in predicting the activation of PPARγ by a 
mixture containing a full (rosiglitazone) and partial (nTZDpa) agonist. At high combined 
concentrations, the activation of PPARγ was reduced by nTZDpa, and this was predicted 
by GCA (Figure 4.2d). Because of overt toxicity and the comparable potencies between 
rosiglitazone and nTZDpa, nTZDpa could not be added to a level that fully reduced the 
activity of the mixture to that of the maximum effect of nTZDpa. However, GCA was 
able to model the decrease in mixture effect, whereas the TEF model, in assuming equal 
efficacy between the two components (and using rosiglitazone as the reference 
compound), inflated the effect of high concentrations of nTZDpa (Figure 4.2c). ES and 
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IA proved inadequate as well (Figure 4.2a). These results indicate that GCA is a viable 
model in the case of two chemicals designed specifically as PPARγ ligands. 
Phthalates comprise a group of chemicals designed for use in products and 
manufacturing but also show biological activity. Manufactured at high volume for use as 
plasticizing agents and flame retardants, phthalates can act on numerous targets, 
especially in the male reproductive system.(267–269) Specific phthalate esters (MEHP, 
MBzP, MBP, and BBP) have also been shown to activate PPARγ.(64,270) Exposure to 
phthalates is widespread and detected in human biomonitoring data, including National 
Health and Nutrition Examination Survey.(271,272) Parent phthalate compounds such as 
DEHP and BBP undergo biotransformation to multiple metabolites following absorption, 
making phthalate mixtures biologically relevant.(273,274) Typically, phthalate metabolites 
are more biologically active than the parent compounds with regard to activation of 
PPARs.(64,275) 
To identify phthalates that activate PPARγ, we used EPA’s ToxCast database (US 
EPA, 2014). Because our assay uses a transfected luciferase reporter construct under the 
transcriptional control of a peroxisome proliferator response element, we selected 
compounds that activated an equivalent model assay in ToxCast. To increase the 
specificity for identifying PPARγ ligands, we included chemicals that also activated a 
PPARγ ligand binding domain fused with a Gal-4 reporter, and excluded chemicals that 
showed any activity in assays for PPARγ’s permissive heterodimer partner, RXRα. 
Contrary to the ToxCast screen, DEHP did not activate PPARγ transcriptional activity in 
our assay. We speculate that this is due to differences in the source of the cell line 
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(human liver in ToxCast, African Green monkey for Cos-7 cells in our assay), though 
others have shown that DEHP does not activate human PPARγ in vitro.(64)  
In a binary mixture, MEHP reduced the activation of PPARγ by rosiglitazone at 
higher concentrations of both compounds, which was predicted by GCA (Figure 4.3c and 
4.3f). GCA also accurately predicted the activation of PPARγ by a more complex 
phthalate mixture. However, ES, IA and TEF all approximated GCA and fit the observed 
data at low concentrations of both rays. In contrast to our results, Silva et al. (2002) 
demonstrated that ES and IA do not sufficiently predict mixture effects of estrogen 
receptor full agonists at low concentrations; this is caused by the non-linear shape of the 
dose-response curves for these compounds at low doses.(259) Our dose-response data are 
nearly linear at low doses (equation 1). As a result, the predictions of ES and IA 
approximate those of GCA. One would not expect the dramatic “Something from 
Nothing” effect that can occur with mixtures that have sub-linear dose-response 
curves.(259)  
When we extrapolate these models to higher dose levels of the phthalate mixture 
(where the dose-response curve departs from linearity) we see considerable divergence 
among the models (Figure 4.5). We also see this pattern in the effect summation 
prediction of the mixture of rosiglitazone and nTZDpa (Figure 4.2a), where effect 
summation overestimates the effect of the mixture at high concentrations. 
GCA requires that the user specify a dose-response function that can be inverted 
yielding real numbers for effect levels of interest. Based on the biological mechanism of 
PPARγ, where ligands bind the receptor at a single site, we used a Hill function with a 
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Hill coefficient of 1.(254,255) This function meets the invertibility requirement. Some 
scenarios may warrant fitting dose-response data with different dose-response functions. 
For example, ligands for receptors that homodimerize (e.g., estrogen receptor) would be 
expected to be non-linear at low dose. We would not expect such data to be adequately fit 
by a Hill function with a Hill coefficient of 1; on the other hand, use of a Hill function of 
2 would violate the invertibility requirement needed for applying GCA to partial agonists. 
We are currently working on appropriate biologically-based models for these types of 
systems. GCA may not be applicable to all mixtures of full and partial agonists. 
Accordingly, careful consideration should be placed on properly specifying the individual 
dose-response functions. 
As an alternative to GCA, Scholze et al. (2014) introduced the Toxic Unit 
Extrapolation model for predicting the joint effect of a mixture that includes partial 
agonists, and applied it to ligands of the estrogen receptor.(276) However, toxic unit 
extrapolation does not account for the antagonistic effect of partial agonists at high doses; 
this effect may in principle occur even when there are two binding sites as in a 
homodimer. We attempted to limit our biological mechanism exclusively to PPARγ-
specific binding via our selection of candidate compounds. Future work will address 
whether concentration additive models are appropriate for cases involving agonist 
mixtures that activate separate components of permissive heterodimers, or whether it is 
better fit by an IA model.  
Although TEF overestimates the mixture response, the model does have the 
advantage of easy interpretability and use, as each component is treated as a dilution of a 
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well-characterized reference compound (for PPARγ, we used rosiglitazone). For 
regulatory purposes, TEF would provide conservative estimates that may be of use to risk 
assessors, where applicable. On the other hand, the model prediction is dependent on the 
choice of reference compound and its efficacy; the model overestimation will increase 
with increasing efficacy of the reference compound. Given the variety of sources, 
structures, and pharmacodynamics (e.g. as shown by Tan et al., 2012)(277) of PPARγ 
agonists, the choice of a ‘correct’ reference compound for PPARγ agonism is not clear.  
Realistic exposures to environmental endocrine disrupting compounds tend to be 
at low concentrations, where GCA, TEF, IA and ES produced similar results for PPARγ 
ligands. However, GCA produced estimates quite different from the other models when 
the mixture concentration was extrapolated to high doses. For PPARγ ligands, GCA may 
be particularly useful in determining effects of interactions between environmental 
exposures and therapeutic treatments. PPARγ already serves as a relevant model for this 
type of mixture, given its well-established role as a target for insulin-sensitizing drugs. 
For example, Cmax estimates of rosiglitazone in human blood during therapeutic use range 
from 200nM to 1.2 uM,(278) concentrations that fall within the drug’s maximal efficacy 
for PPARγ activation. When co-exposure to low efficacy environmental PPARγ ligands 
occurs, the efficacy of the administered therapeutic may be reduced. Given the breadth of 
PPARγ’s biologic influence and the increasing number of identified ligands in the built 
environment, future studies should characterize mixture effects on relevant endpoints 
under control of PPARγ activation, such as insulin sensitivity and lipid accumulation, to 
better inform the biology behind predictive models.  
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Tables 
Table 4.1. Modeled parameters for phthalate compounds from dose-response fits using 3-parameter Hill equation (with 
Hill coefficient of 1) (Figure 4.4a and 4.4b). 
 DEHP MEHP BBP MBP MBzP 
EC50 (M) 
(95% CI) 
N.D. * 2.2 x 10-5 
(9.8 x 10-6, 
4.7 x 10-5) 
1.7 x 10-5 
(7.9 x 10-6, 
3.6 x 10-5) 
5.1 x 10-5 
(1.5 x 10-5, 
1.7 x 10-4) 
1.6 x 10-4 
(8.3 x 10-5, 
3.0 x 10-4) 
Span (max–min) 
(95% CI) 
N.D. 1.3 
(1.0, 1.6) 
1.0 
(0.89, 1.2) 
0.61 
(0.42, 0.79) 
2.5 
(1.9, 3.1) 
Efficacy relative to 
Rosiglitazone maximum (2.3-
fold change (95% CI: 2.0, 2.6)) 
N.D. 0.56 0.43 0.26 1.1 
R2 N.D. 0.87 0.88 0.71 0.90 
 
DEHP: di-ethyl hexyl phthalate; MEHP: mono-ethyl hexyl phthalate; BBzP: butyl benzyl phthalate; MBP: mono-butyl 
phthalate; MBzP: mono-benzyl phthalate. * N.D. (not detected): Because of the minimal efficacy and poor statistical fit, DEHP 
was considered to be inactive for the purpose of the mixture experiments. 95% CI: 95% Confidence Interval associated with fit 
estimate. Span: difference in estimated curve maximum and curve minimum (see Equation 1).  
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Table 4.2. Phthalate components of mixture rays. Ray A: phthalates mixed at initial concentrations below calculated 
EC10 from individual dose-response curves. Ray B: phthalates mixed at initial concentrations producing the equivalent 
effect as rosiglitazone EC10 from control dose-response curve (Figures 4.4a and 4.4b).  
 
  MEHP BBzP MBP MBzP Stock mixture concentration 
(total) 
Ray A Concentration 
(M) in stock 
mixture 
2.2 x 10-6 1.7 x 10-6 4.3 x 10-6 1.6 x 10-5 2.4 x 10-5 M 
Effect 
level % max 
9.3 9.2 7.7 9.5  
Ray B Concentration 
(M) in stock 
mixture 
3.8 x 10-6 3.7 x 10-6 1.5 x 10-5 1.6 x 10-5 3.9 x 10-5 M 
Effect 
level % max 
15 18 23 9.4  
 
Note: DEHP excluded from rays (see footnote in table 1)
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Figures 
FIGURE 4.1.  The maximal response of rosiglitazone is decreased by high doses of 
nTZDpa. 
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Figure 4.1. The maximal response to rosiglitazone is decreased by high 
concentrations of nTZDpa. a. Individual (marginal) dose-response curves of Rosiglitazone 
(full agonist) and nTZDpa (partial agonist). Cos-7 cells were transfected with peroxisome 
proliferator response element-dependent 3x luciferase reporter as described in Methods and 
dosed with Vh (dimethyl sulfoxide) or the indicated concentrations of agonist. Green 
fluorescent protein fluorescence-normalized luminescence was normalized to that of 
untreated culture wells. EC50 rosiglitazone: 2.2 x 10-8 M; EC50 nTZDpa: 7.1 x 10-8 M. n = 4 
separate transfections. b. Dose-response curves of rosiglitazone in combination with 
increasing partial agonist concentration (error bars: SEM), (n = 4). 
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FIGURE 4.2.  GCA provides an accurate prediction of full and partial PPARγ 
agonist mixture effects.
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Figure 4.2. GCA provides an accurate prediction of full and partial PPARγ agonist 
mixture effects. a.) Experimental joint dose-response surface of Rosiglitazone and nTZDpa 
dose combinations. Vertical axis: fold change in PPARγ activation over untreated cultures 
(linear). Marginal curves correspond to individual dose-response curves shown in Figure 4.1. 
b.) Effect Summation (ES), c.) Independent Action (IA), d.) Toxic Equivalency Factor (TEF), 
and e.) GCA model fits based on parameters (with Hill coefficient constrained at 1.0) listed in 
embedded table and formulations listed in Methods.
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FIGURE 4.3.  Phthalate esters activate PPARγ with a variety of efficacies. 
144 
 
 
1
4
4
 
Figure 4.3. Phthalate esters activate PPARγ with varying efficacies. Cos-7 cells were 
transfected with peroxisome proliferator response element-dependent 3x luciferase reporter 
as described in Methods and dosed with Vh (DMSO) or the indicated concentrations of 
agonist. GFP fluorescence-normalized luminescence was normalized to that of untreated 
culture wells. Positive control data (rosiglitazone) included for comparison. n = 4 separate 
transfections. a.) Dose-response curves of parent phthalates DEHP and BBP. b.) Dose-
response curves of metabolite phthalate compounds MEHP, MBP, and MBzP. c.) 
Rosiglitazone dose-response curves with increasing concentrations of MEHP. Error bars 
omitted for clarity. All curves fit with a 3-parameter Hill equation (with Hill coefficient 
constrained at 1). Dose response parameters for phthalate components are listed in Table 1. 
d.) Experimental dose-response surface e.) TEF-predicted surface f.) GCA-predicted surface 
of rosiglitazone/MEHP mixture. Interior values predicted using parameters derived from 3a. 
(Rosiglitazone EC50: 2.3 x 10-8 M) and Table 1. Rosiglitazone dose-response curves by 
increasing MEHP are labeled i. – iv. to facilitate comparison to 4.3c.
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FIGURE 4.4. Comparison of experimentally determined PPARγ activation, using phthalate ray design, with model 
predictions. 
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Figure 4.4. Comparison of experimentally determined PPARγ activation (fold 
change over untreated cells), using phthalate ray design, with model predictions. a.) 
Phthalates combined at starting concentrations below individual EC10. b.) Phthalates 
combined at starting concentrations producing effect levels equal to 10% of 
rosiglitazone’s maximal effect. c.) Comparison of rays and models at highest 
concentrations. TEF: Toxic Equivalency Factor model; ES: Effect Summation model; IA: 
Independent Action model; GCA: Generalized Concentration Addition model. Ray 
design specifications listed in table 2. Experimental data n = 4 separate transfections, 
mean +/- SEM. Baseline: Experimental curve fit estimated minimum (experimental curve 
fit omitted for clarity).   
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FIGURE 4.5.  Extrapolations of modeled dose-responses to high concentrations for 
ray A. 
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Figure 4.5. Extrapolations of modeled dose-responses to high concentrations for ray 
A. Vertical line: maximum mixture concentration tested (figure 4.4a).  
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Supplemental material 
Supplementary Figure S4.1 
 
  
150 
 
 
1
5
0
 
Supplementary Figure S4.1. GCA provides an accurate prediction of full (rosiglitazone) 
and partial (nTZDpa) PPARγ agonist mixture effects. a.) 3D surface plots of experimental 
data depicting mean values (left column), mean plus SEM (center column) and mean 
minus SEM (right column) values (n = 4 separate experiments). GCA (b.), TEF (c.), IA 
(d.) and ES (e.) surface plots were constructed by inputting the mean, mean-plus-SEM or 
mean-minus-SEM values of marginal curves (GCA, TEF) or response (ES, IA) to models 
as described in methods. SEE: standard error of estimate (model distribution versus 
corresponding experimental distribution) defined as  
𝑆𝐸𝐸 =  √
∑(𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑣𝑎𝑙𝑢𝑒 − 𝑚𝑜𝑑𝑒𝑙𝑒𝑑 𝑣𝑎𝑙𝑢𝑒)2
𝑁
 
Where N = number of paired values = 36. GCA consistently provides the best fit (i.e. 
lowest SEE) and appears the least sensitive to changes in input values. 
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CHAPTER V:  Conclusions 
 
This research was designed to determine the mechanisms of toxicant-induced 
bone outcomes specifically as they relate to coordinate activation of nuclear receptors in 
bone cells. We used murine in vitro and in vivo models to experimentally identify 
important changes in gene expression and phenotype resulting from exposure to 
environmental toxicants that bind and activate the peroxisome proliferator activated 
receptor gamma (PPARγ). The first study characterized an important negative correlation 
between adipogenesis and osteogenesis in developing bone cells treated with 
environmental PPARγ ligands, and found that the dual PPARγ/RXRα agonist organotins 
disproportionately suppress osteogenesis (Chapter 2). In the second study, we exposed 
adult, female C57Bl/6 mice to tributyltin (TBT) and observed a unique phenotype 
characterized by a suppression of both cortical bone apposition and trabecular bone 
resorption, and determined that a perturbation of normal osteoclast differentiation and 
function contributed to an increased osteoblast stimulus where bone turnover is prevalent 
(Chapter 3). Last, we contributed to the field of toxicological mixtures by establishing the 
utility of Generalized Concentration Addition in modeling the additive effects of 
environmental PPARγ agonists (demonstrated with phthalate parent and metabolite 
compounds) (Chapter 4). 
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Chapter 2: Structurally-diverse, PPARγ-activating environmental toxicants induce 
adipogenesis and suppress osteogenesis in bone marrow mesenchymal stromal cells 
This study used in vitro murine, bone marrow mesenchymal stromal (BM-MSC) 
cell cultures to characterize the changes in gene expression and bone and fat formation 
that are indicative of an adipogenic skewing of BM-MSC differentiation in response to 
PPARγ activation. Under osteogenic conditions, primary BM-MSCs were exposed to a 
set of diverse environmental toxicants already shown to activate PPARγ. With varying 
efficacies and potencies, these compounds suppressed expression of osteogenic genes 
Runx2, Sp7, and Dmp1 concomitant with increases in adipogenic genes Fabp4 and Plin1. 
These changes were accompanied by proportional suppression of alkaline phosphatase 
activity, bone nodule formation, and mineralization in parallel with increased lipid 
accumulation. Together, these experiments reinforced the current paradigm asserting that 
there is a trade-off between adipogenesis and osteogenesis in differentiating BM-MSCs, 
and that PPARγ activation can instigate this trade-off. However, the organotin 
compounds (TBT and triphenyltin) suppressed bone formation with a distinct efficacy. 
We speculated that this difference was, in part, attributable to the dual PPARγ:RXRα 
agonist nature of these compounds. These studies highlighted an important mechanism by 
which PPARγ activation, particularly by environmental agents, can regulate bone quality. 
The primary limitation to this study was the in vitro methodology. Although this 
setup allowed for precise determination of gene transcription and differentiation markers 
in osteoblasts, the bone marrow is a complex environment consisting of numerous cell 
types that intercommunicate. As such, these influences were not taken into account. 
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Chapter 3 addressed this limitation by using an in vivo model, however, the conclusions 
from Chapter 2 – suppression of osteoblast differentiation and bone formation – had led 
us to hypothesize that overall bone quality would be decreased with in vivo exposure to 
TBT, especially given that TBT appears to be disproportionately efficacious in this 
regard.  
Although we characterized novel toxic effects for several compounds in this study 
(e.g. TBBPA and METBP), this in vitro design limitation points to the fact that in 
determining a critical effect of a toxicant, an in vitro model is not sufficient on its own 
(though identifying new critical effects was not our stated intent). PPARγ activation does 
effectively suppress osteoblastogenesis in favor of adipogenesis to decrease bone quality, 
and this is supported by in vivo data using rosiglitazone. However, we surmised that 
additional nuclear receptor activity, namely RXRα activation, can modify this effect. 
Thus, these outcomes may be affected by even the most proximal events of differential 
nuclear receptor activation. Building on these data, more precise mechanisms involving 
the RXR will be investigated in primary osteoblast BM-MSC cultures to determine if the 
dual ligand nature of organotins is indeed consequential. In particular, three questions 
may be asked: does activation of an RXR homodimer alone by TBT sufficiently suppress 
osteoblast differentiation? Is there a simultaneous, dual binding of PPARγ and RXRα by 
TBT that functions additively or synergistically? Or is this an effect of RXRα dimerizing 
with another nuclear receptor (e.g. LXR) to activate an independent pathway that also 
suppresses osteoblast differentiation? We have generated preliminary (Chapter 3 
supplemental) and published(80) data to establish the activation of additional pathways by 
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TBT, though their relative contributions to TBT’s disproportionate efficacy in 
suppressing osteoblast differentiation specifically has not been determined.  
 
Chapter 3: Tributyltin induces distinct effects on cortical and trabecular bone in female 
C57Bl/6J mice resulting from modulation of both osteoblasts and osteoclasts  
Here, 12-week old, female, wild-type C57Bl/6 mice were exposed to 10 mg/kg 
TBT (or a sesame oil vehicle) for 10 weeks via oral gavage. Long bone samples were 
collected for micro architectural structure, histological analysis, and whole bone gene 
expression. Micro-computed tomography (micro-CT) analysis identified that the mid-
diaphysis of the treated animals was smaller in cross-sectional area, though the medullary 
space decreased in size with the cortical thickness; the percentage of bone area to total 
area was maintained. The trabecular compartment at the distal metaphysis was more 
heavily mineralized in TBT-treated animals compared to controls, with an increase in 
bone density, trabecular number, and thickness, and a decrease in inter-trabecular 
spacing. Histological analyses showed that trabecular osteoclast coverage was not 
affected by treatment with TBT, suggesting that the function of the osteoclasts, and not 
prevalence, had been compromised to decrease bone resorption. Whole bone mRNA 
analyses showed significant decreases in osteoclast differentiation and functional markers 
Nfatc1, Trap, and Ctsk. Additionally, there was a significant increase in expression of Ct-
1, which codes for a pro-osteoblast cytokine, cardiotrophin-1. These results were 
interpreted as a TBT-induced shift in the osteoclast population to one that is functionally 
deficient in resorption but still capable of stimulating osteoblastogenesis in an area of 
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high bone turnover (the trabeculae), as is seen in some models of osteopetrosis. In vitro 
primary osteoclast cultures supported this interpretation, recapitulating the pattern of 
gene expression with TBT treatment seen in whole bone mRNA. Furthermore, TBT 
treatment did not reduce the number of TRAP-positive, multinucleated cells cultured with 
RANKL and MCSF compared to vehicle (DMSO) treatment. However, TBT does still 
seem capable of suppressing osteoblast activity in an area of low bone turnover, as 
evidenced by the decreased bone apposition at the midshaft.  
Because the micro-CT data is representative of a single time point, we are forced 
to only hypothesize that bone apposition is not occurring at the periosteal surface in 
treated mice (as opposed to bone loss). In comparison to untreated, 3 month-old 
animals,(153) there was a modest increase in total cross-sectional area in the TBT-treated 
mice after 10 weeks of treatment, though it was smaller than the increase observed in 
vehicle-treated mice. This implies a stunted outward growth of cortical bone in TBT-
treated mice. The use of dynamic histomorphometry to obtain a time-lapse of bone 
deposition over the course of a 10-week treatment regime will definitively establish 
whether periosteal bone apposition – and thus suppression of osteoblast activity – is in 
fact an endpoint of TBT exposure. This would corroborate findings such as those of 
Chapter 2, as well as help parse the apparent paradoxical observation of bone suppression 
in one compartment (cortical shell) and bone deposition in another (trabecular 
compartment). We hypothesize that in the absence of osteoclasts (such as along the 
periosteum), the predominant effect of TBT is suppression of osteoblast differentiation; 
in the presence of osteoclasts, indirect osteogenic stimulation predominates.  
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An important finding of this study was that TBT activates multiple nuclear 
receptor pathways in osteoclasts. The in vitro data confirmed that TBT can suppress 
normal osteoclast function, however, the correlation in these results with other nuclear 
receptor-specific ligands (e.g. LG100268 (RXRα) or T0901317 (LXRα and LXRβ) is 
circumstantial without the use of antagonist or knockout models. Antagonism of the 
LXR, for instance, may remove some of this inhibitory effect, as others have shown that 
LXR activation plays a suppressive role in osteoclast differentiation.(13,235,279) RXRα 
activation has been shown to modify osteoclast differentiation as well.(13) RXR 
heterodimer-specific ligands have been developed, as have LXRα and LXRβ knockout 
mice from which bone marrow can be cultured. Future studies will take advantage of 
these resources to more precisely determine the contribution of RXR heterodimers to 
osteoclast function.  
The use of ex vivo osteoclast cultures from TBT-treated mice may also be 
informative, as they would provide an assessment of the potential for TBT-exposed pre-
osteoclasts to differentiate under normal conditions. A recent study showed that RXR 
homodimer activation plays a role in the early differentiation of osteoclasts (i.e. a proper 
response to MCSF), whereas RXR:LXR activation is influential in osteoclast response to 
RANKL.(13) The present in vitro studies only applied nuclear receptor ligands to 
osteoclasts after an initial RANKL exposure. Thus, the mechanisms of action of these 
agonists as they relate to events upstream of RANK activation and Nfatc1 expression are 
not fully investigated. These experiments would also help identify whether the 
hypothesized shift of osteoclasts to a subtype that sustains osteoblast signaling despite 
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losing resorptive capacity is established early in osteoclast differentiation or later, after 
the osteoclast has matured. 
In spite of these limitations, this study provided further evidence that RXR is an 
important factor in osteoclast-mediated bone homeostasis, demonstrated for the first time 
(to our knowledge) a pro-osteogenic effect of an RXR or (indirect) LXR ligand in an 
intact mouse model, and suggested the possibility that obesogenic compounds may have 
wider ranging influences in perturbing normal bone turnover beyond PPARγ-specific 
effects. As the list of PPARγ-activating chemicals grows, attention should be focused on 
the permissive aspect of the PPARγ:RXRα heterodimer so as to not preclude the 
activation of alternate pathways. For instance, the use of PPARγ:RXRα heterodimers in 
in vitro screening assays has been criticized for the potential for non-specific, off-target 
effects.(71) However, this study demonstrates that such results may in fact be informative 
and help expand a given chemical’s known mechanism of action, as shown here.  
 
Chapter 4: Generalized Concentration Addition modeling predicts mixture effects of 
environmental PPARγ agonists 
Generalized Concentration Addition (GCA) is an additive model that was 
developed to address a limitation inherent to other concentration additive models (such as 
the toxic equivalency factor model, TEF): the joint effects of two (or more) chemicals 
cannot be accurately predicted at a level greater than the efficacy of the least efficacious 
component. Due to receptor-ligand pharmacodynamics, the efficacies of mixture 
components tend to differ, making GCA a useful model for predicting high mixture effect 
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levels. Though GCA’s application to PPARγ was plausible in theory, it had not been 
demonstrated that this modeling strategy could predict the combined effects of a mixture 
of PPARγ agonists. In these experiments, dose-response curves of individual PPARγ 
ligands were generated using a luciferase reporter gene under control of a DR-1 response 
element in Cos-7 cells. A binary (rosiglitazone and the partial agonist nTZDpa) and a 
complex mixture (phthalate parent compounds and metabolites identified as PPARγ-
specific agonists in ToxCast) of PPARγ-activating chemicals were each applied to the 
luciferase assay. Using parameters estimated from the individual component dose-
response curves, mixture effects were predicted under different additive models and 
compared to the empirical mixtures data. Generalized Concentration Addition was able to 
accurately model the empirical data despite the variety of efficacies among the mixture 
components, whereas TEF could not, and the effect summation and independent action 
models were only accurate at low doses where the individual curves were approximately 
linear. Because an increasing number of environmental PPARγ agonists are being 
identified, thus increasing the likelihood of PPARγ ligand mixture exposures, this study 
provides an important basis for determining the most appropriate model to use. These 
results support the use of Generalized Concentration Addition in modeling the effect of a 
mixture of PPARγ-specific ligands, provided certain assumptions of PPARγ-specific 
activity are true. 
The design of the complex mixture studies relied on the assumption that the 
compounds only bound and activated PPARγ, and not RXRα additionally. Under this 
assumption, the mixture should show attenuated effects at levels where a partial agonist 
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would antagonize the receptor:full agonist complex.(17) We were only able to obtain data 
to observe this effect at the highest concentration of our ray design, as each component 
was added to the mixture at sub-maximal concentrations (at or less than the individual 
EC10). However, a binary mixture with rosiglitazone and one phthalate (MEHP) did 
show the competitive antagonism effect expected under our assumption of one binding 
site (i.e. PPARγ specificity), and the selection of compounds was in part based on criteria 
that RXRα-activation assays were null.  
However, it is known that TBT can activate both members of the PPARγ:RXRα 
heterodimer.(63) In this scenario, a second binding site is presented, which may 
circumvent the competitive antagonism effect of a second, PPARγ-specific partial 
agonist, such as nTZDpa. Preliminary data (not shown) have suggested that this is the 
case, as the reduction in response element activation is not observed at high combination 
doses of TBT and nTZDpa as it is with a rosiglitazone/nTZDpa mixture. The 
permissiveness of the PPARγ:RXRα heterodimer allows for activation by either agonist: 
the low-efficacy PPARγ agonist should not therefore act as an antagonist to TBT on 
RXRα. Because TBT can also bind and activate an RXR homodimer, the observed 
response could also be due to a combination of PPARγ:RXRα heterodimer and 
RXRα:RXRα homodimer activity. In either case, we hypothesize that such situations 
would not be GCA. Use of heterodimer-specific RXR agonists and antagonists, as in 
Chapter 3’s future studies, will again provide important insights into the behavior of the 
PPARγ:RXRα heterodimer and potentially other receptor pairings and their activation by 
chemical mixtures. 
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Public health implications 
A well-maintained balance of bone formation and resorption is essential for long 
term bone health. Our results with TBT suggested that the chemical induces an 
osteopetrosis-like phenotype in the trabecular compartment. Osteopetrosis as a disorder 
encompasses a number of different pathologies that are generally characterized by failure 
of osteoclast function.(243) These disorders are inherited,(88) and exogenous factors that 
significantly contribute to the onset of osteopetrosis are not established in the literature. It 
may be that TBT’s mechanism of action to suppress osteoclast function represents a 
potential risk for decreased bone resorption. As this balance is upset in the high-turnover 
trabecular space, there are potential complications for proper calcium and phosphate 
homeostasis. For instance, women may lose up to 10% of bone mineral density during 
pregnancy and nursing to provide calcium for the developing fetal and infant 
skeleton.(170,280) Exposure to TBT or a similar-acting compound may severely attenuate 
the mobilization of minerals during this important window of susceptibility.  
Because TBT appears to increase trabecular density, a diagnosis of osteoporosis 
in exposed individuals would not seem likely. However, the effect of TBT to thin the 
bone, via decreasing the cross-sectional area at the mid-shaft, represents a potentially 
serious pathology. Thinner bones are more susceptible to fracture,(140) and bone fractures 
have substantial associations with mortality, particularly in the elderly population. For 
example, in some populations the excess age-adjusted mortality rate in the first year after 
a hip fracture has been found to be as high as 20% in women, and higher in men.(281) 
Women who experience a hip fracture may have up to five times the odds of mortality 
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within the first year following the fracture.(282) The risk of fracture is significantly 
increased with a prior fracture,(283) even if asymptomatic.(281) The mortality rates decline 
by year following the fracture, eventually returning to background rates,(282) though 
quality of life is unquestionably impacted.(284,285) It should be noted that a number of 
these studies showing the most drastic effects have focused exclusively on white women, 
thereby limiting the generalizability to other populations. However, the world population 
as a whole is ageing and the incidence of fractures is accordingly expected to 
increase.(286)  
The exact contribution of environmental exposures to the incidence of fractures 
on a population level is, at this point, not quantifiable, although some studies are 
beginning to identify important biological covariates in predicting fracture risk.(287) Even 
if epidemiologic evidence is unattainable in the short-term, mechanistic investigations of 
bone modifying agents are valuable. Importantly, a diagnosis of low bone density is 
usually not given until after a traumatic event. Osteoporosis has been termed a “silent” 
disease, in that it tends to not be recognized until a fracture occurs, and its prevalence in 
the United States alone is expected to exceed 14 million individuals by 2020, when it is 
estimated that one in two individuals will be at risk.(227) Hence, studying the etiology of 
low bone density and decreased bone apposition is important in identifying preventative 
measures. In light of the mechanisms related to environmental PPARγ/RXRα agonist 
exposures, it is reasonable to speculate that any exogenous modifiers of bone that either 
predispose individuals to fractures later in life (i.e. by suppressing bone apposition during 
development and reducing peak bone mass) or diminish proper bone maintenance and 
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turnover in mature bone will have a realistic influence on fracture risk.  
Environmental levels of TBT have decreased in the past decade thanks to 
regulatory efforts.(288) With environmental exposures and biomarker levels generally 
decreasing, tributyltin is becoming less relevant as an environmental toxicant to 
humans.(213,256,289,290) However, these studies show a potential utility of TBT to serve as a 
model ligand to probe the mechanisms of the PPARγ:RXRα heterodimer. The use of a 
toxicant to study mechanisms of disease is not a novel concept (for example, aryl 
hydrocarbon receptor-activating compounds are frequently used to identify important 
pathways in cancer).(291,292) Using appropriate knockout mouse models in conjunction 
with TBT as a multi-functional agonist may help in elucidating the mechanisms behind 
RXRα-, LXR-, or PPARγ-mediated mechanisms in bone, ultimately contributing to the 
development of therapeutics.  
Although TBT’s relevance as an environmental threat to humans may be waning 
due to successful regulatory measures, PPARγ has gained attention recently as a target of 
an increasing number of environmental obesogen compounds. Recent work has 
investigated PPARγ’s role in changing the adipogenic ‘setpoint’ during development, 
predisposing individuals to obesity later in life when exposed perinatally.(60,61) Our 
studies confirm its influence in suppression of osteoblastogenesis and increases in bone 
marrow fat content, which also may be considered a targeted obesity outcome that can 
have lifelong effects from early life exposures. Accordingly, the mechanistic 
consequences of PPARγ and/or RXRα activation in bone disease should be taken into 
consideration in developing toxicological screens for environmental ligands. These data 
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can further inform mixture analyses that rely on experimentally based and precise 
mechanistic information to increase their predictive ability. PPARγ and its ligands sit at a 
union of increasing environmental prevalence and toxicological relevance, and thus 
provide a robust example of the important role of nuclear receptors in environmental 
health.  
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